

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 0
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 0
- 1
- 2
- 3
- 4
- 5

RETRACTABLE TECHNOLOGIES	*	Civil Docket No.
INC.	*	
	*	2:07-CV-250
VS.	*	Marshall, Texas
	*	
	*	November 2, 2009
BECTON DICKINSON & COMPANY	*	8:45 A.M.

TRANSCRIPT OF JURY TRIAL
BEFORE THE HONORABLE DAVID FOLSOM
UNITED STATES DISTRICT JUDGE

APPEARANCES:

FOR THE PLAINTIFF:

MR. ROY W. HARDIN
MR. GEORGE E. BOWLES
MR. STEPHEN D. WILSON
MR. MARK R. BACKOFEN
Locke Lord Bissell & Liddell
2200 Rose Avenue, Suite 2200
Dallas, TX 75201

MR. OTIS CARROLL
MS. DEBORAH RACE
Ireland, Carroll & Kelley
6101 So. Broadway, Suite 500
Tyler, Texas 75703

APPEARANCES CONTINUED ON NEXT PAGE:

COURT REPORTERS: MS. SUSAN SIMMONS, CSR
MS. JUDITH WERLINGER, CSR
Official Court Reporters
100 East Houston, Suite 125
Marshall, TX 75670
903/935-3868

(Proceedings recorded by mechanical stenography,
transcript produced on CAT system.)

1 APPEARANCES CONTINUED:

2
3
4 FOR THE DEFENDANT: MR. DAVID J. BECK
MR. ALISTAIR B. DAWSON
5 Beck Redden & Secrest
One Houston Center
6 1221 McKinney, Suite 4500
Houston, TX 77010

7
8 MS. LISA J. PIROZZOLO
Wilmer Cutler Pickering
Hale and Dorr
9 60 State Street
Boston, MA 02109

10
11 MR. W. DAVID CARTER
Mercy Carter and Tidwell
12 1724 Galleria Oaks Drive
Texarkana, TX 75503

13 * * * * *

14
15 P R O C E E D I N G S

16
17 (Jury out.)

18 COURT SECURITY OFFICER: All rise.

19 THE COURT: As a matter of fact of
20 housekeeping, I believe the Court was notified by
21 e-mail, but it's not part of the record, that the
22 Plaintiff wishes to dismiss its DOE claim, is that
23 correct, of infringement?

24 MR. HARDIN: That is correct, Your Honor.

25 THE COURT: And the Defendants wish to --

1 or Defendant -- dismiss certain invalidity claims; is
2 that correct?

3 MR. BECK: That is correct, Your Honor.

4 THE COURT: And what are those, for
5 purpose of the record, or can we have some written
6 stipulation later in the day?

7 MR. BECK: We will, Your Honor, a written
8 stipulation later.

9 MR. HARDIN: That's fine, Your Honor.

10 THE COURT: Very well.

11 I considered the motion concerning the
12 limiting instruction that's part of the record as a
13 result of Mr. Beck's statement during opening. And I'm
14 of the opinion, since the DOE claim was still in at the
15 time, that that was not a violation of the Court's
16 limine order and will deny the requested instruction.

17 Any other matters?

18 It's my understanding Plaintiff wishes to
19 use a little short time --

20 MR. CARROLL: That's correct, Your Honor.

21 THE COURT: Then the Defendant will let
22 us know, after you hear it, whether you want to respond.

23 MR. BECK: That is correct.

24 THE COURT: Very well. Let's bring the
25 jury in, and then we'll start today's testimony.

1 (Jury in.)

2 THE COURT: Please be seated, Ladies and
3 Gentlemen.

4 Good morning. I hope everyone had a
5 pleasant weekend.

6 Very shortly, we will start testimony in
7 the trial, but I've given each side of the case up to 30
8 minutes during the course of the trial to make what we
9 call interim statement, with no more than five minutes
10 being used at any one time.

11 And the Plaintiff wishes to exercise up
12 to five minutes of that time. And if the Defendant
13 wishes to respond, they're entitled to do so up to five
14 minutes.

15 Mr. Carroll.

16 MR. CARROLL: Thank you, Your Honor. If
17 the Court please.

18 Good morning.

19 THE JURY: Good morning.

20 MR. CARROLL: You have with you your jury
21 notebook. This is kind of like for a football player,
22 your playbook. And I want to talk to you just a little
23 bit this morning --

24 THE COURT: Mr. Carroll, do I have a
25 copy, or do you have an extra copy for me?

1 MR. CARROLL: You can sure have mine,
2 Judge.

3 Do we have an extra one?

4 THE COURT: I have one right here.

5 MR. CARROLL: Okay.

6 THE COURT: I will take my clerk's, so if
7 you have an extra copy for them.

8 MR. CARROLL: I will give them mine,
9 Judge. If I can remember what page I'm on.

10 LAW CLERK: You can have it.

11 MR. CARROLL: Can I give it to you
12 afterwards? Thank you.

13 So in my opinion, the significance of
14 this notebook is that it will give you a way to keep up
15 today, and every day, in two regards.

16 First of all, you'll look that the
17 patents are in the -- in the notebook. The patents --
18 remember, we have patents that are at issue in this case
19 issued by the government, and we claim they are
20 infringing or trespassing on our patents.

21 The patents are in here, and that's the
22 first three tabs.

23 The fourth tab is a very, very important
24 tab. The fourth tab -- and if everybody would turn to
25 that and look up at the top -- everybody on the fourth

1 tab?

2 Look up at the top, and you'll see the
3 word -- there's a chart there -- Tab 4. Okay. And
4 you'll see up at the left hand -- up at the top on the
5 left hand, it says term. Then on the right hand, it
6 says Court's construction.

7 Remember, Judge Folsom told you there
8 were two judges: The fact judges, which are you-all,
9 and law judges, which is His Honor. That's part of the
10 law judge's job, is to tell us where our fence line is
11 for this patent.

12 Remember, I told you a patent is like a
13 deed, and we're entitled to keep out anybody, without
14 permission, out of our fence line.

15 Judge Folsom tells you where the fence
16 line is. That's why this is important, and this is not
17 for me to decide or for Mr. Beck to decide or for
18 you-all to decide; the Judge has done that.

19 So let me tell you what you're going to
20 hear this morning from us, from RTI, the Plaintiff.

21 We're the one asking for help on this
22 infringement case.

23 Flip over to Page 5 -- I'm sorry --
24 Tab 5, and there's a picture or page with some pictures.
25 Look on the second -- on the left-hand column in the

1 middle picture. That's Ms. Duesman. And she's not too
2 pleased with her picture, but I think it's a good one.

3 And here's -- Ms. Duesman will be our
4 first witness. And I may have told you a little bit
5 about this on Friday, but Ms. Duesman is a registered
6 nurse who has been a registered nurse for 24 years.

7 I told her this morning, I said you've
8 done it almost a quarter of a century. She said that
9 sounds way old, way long. I said, okay, how about 24
10 years? So she's done that 24 years.

11 And let me tell you what she's going to
12 tell you. She's going to tell you why Mr. Shaw's
13 invention did what the patent law calls satisfied a
14 long-felt need. That's a patent term. But what it
15 means is, it solved a problem that was a big problem and
16 an unsolved problem.

17 And she's going to tell you about that
18 from the standpoint of somebody, who has, for a long
19 time, took care of patients. And she's going to tell
20 you how she learned about the Shaw technology and why it
21 caused her not only to join the company as an employee,
22 but how it caused her and her former rancher husband to
23 invest in the company.

24 She -- they really put their mouth---
25 their money where their mouths were. So that's what

1 you're going to hear from Ms. Duesman. She will be the
2 first witness.

3 The second witness is -- let me find my
4 tab here -- the second witness is right under
5 Ms. Duesman's picture, Neil Sheehan.

6 THE COURT: Mr. Carroll, I am told your
7 five minutes has been used. I will give you an
8 additional 30 seconds since we used part of your time
9 trying to locate my copy of --

10 MR. CARROLL: Okay.

11 THE COURT: So if you'll round up your
12 comments in the next 30 seconds.

13 MR. CARROLL: Okay. Neil Sheehan is
14 going to talk about infringement. Let me tell you what
15 he's going to say, and this is very important.

16 He is going to refer you back to Judge
17 Folsom's description of our property line, and he's
18 going to tell you that what's important is not what
19 releases that needle, whether it's cut or torn or
20 anything else, that that's not what Judge Folsom tells
21 you is important.

22 And you'll find that in the book.

23 What's important is what holds it, what
24 holds that spring and holds that needle. And if it's
25 friction, Judge Folsom says, or if it's clamping, Judge

1 Folsom says that's in our fence line.

2 And if you find, based on what you hear
3 from Mr. Sheehan, that they either hold by clamping or
4 friction, regardless of what cuts it loose, whether it's
5 cutting or tearing or anything else, we win.

6 Thank you.

7 THE COURT: Response on behalf of
8 Defendant?

9 MS. PIROZZOLO: No response, but may we
10 approach the bench, Your Honor?

11 THE COURT: Yeah.

12 (Bench conference.)

13 THE COURT: Now, are you taking the
14 witness on cross-examination?

15 MS. PIROZZOLO: No, Your Honor.

16 THE COURT: Okay.

17 MS. PIROZZOLO: Mr. Carroll indicated
18 that Ms. Duesman is going to discuss long-felt need, and
19 I think we need some guidance from the Court, because
20 she wasn't disclosed as an expert in this case.

21 And in addition, the invention here is a
22 particular type of retraction mechanism, and any
23 solution to needlestick injuries is not -- is no nexus.

24 THE COURT: I think she can -- as far as
25 going to the expert witness, I don't think she has to be

1 designated as an expert witness just on general
2 background information, the use of the needle.

3 MR. CARROLL: That's all we're going to
4 do.

5 THE COURT: What's your reply to the
6 second --

7 MR. CARROLL: I guess I didn't understand
8 it. I'm sorry.

9 MS. PIROZZOLO: Okay. The invention here
10 is a particular type of retraction mechanism, not any --
11 any solution to needlestick injuries. So saying that
12 the long-felt need was any type of solution to
13 needlestick injuries, there's no nexus between the
14 claims being asserted against Becton Dickinson, which
15 are a particular type of retraction mechanism and
16 needlestick injuries in general.

17 MR. CARROLL: Okay. Judge, here was my
18 point, and that is, we're going to put her up there to
19 talk about how she found out about this, how she joined
20 the company, what the company is, what they do, and then
21 why -- you know, why she joined us, because she saw a
22 thing on the television, and she thought it was great.

23 THE COURT: Well, obviously raise an
24 objection if he tries to go outside.

25 MR. CARROLL: And I'm not trying to dance

1 around it. I just -- frankly, I don't understand it,
2 but it's my problem, not your problem.

3 MS. PIROZZOLO: Nexus.

4 THE COURT: Obviously don't try to make
5 an expert out of her.

6 MR. CARROLL: Oh, Judge, I'm not. That's
7 the last thing we need is another expert.

8 (Bench conference concluded.)

9 MR. CARROLL: May I proceed?

10 THE COURT: Yes, you may.

11 MR. CARROLL: Your Honor, I don't believe
12 Ms. Duesman has been sworn.

13 THE COURT: Come around, please.

14 Has the Rule been requested?

15 MR. BECK: It has, Your Honor.

16 THE COURT: Very well.

17 Are there any witnesses, other than
18 corporate representatives, individual parties? And I do
19 allow experts to remain in the courtroom from both
20 parties, because they, in part, can arrive at their
21 opinion from what they hear and see in the courtroom.

22 So is anyone subject to the Rule that's
23 in the courtroom?

24 MR. CARROLL: Not from the Plaintiff,
25 Your Honor.

1 THE COURT: If the parties will help me
2 police this.

3 MR. BECK: I don't see anybody from our
4 side either, Your Honor.

5 THE COURT: Very well. Thank you.

6 COURTROOM DEPUTY: Would you raise your
7 right hand.

8 (Witness sworn.)

9 MR. CARROLL: If the Court, please, Your
10 Honor.

11 THE COURT: Yes.

12 KATHRYN DUESMAN, PLAINTIFF'S WITNESS, SWORN

13 DIRECT EXAMINATION

14 BY MR. CARROLL:

15 Q. Ms. Duesman, good morning.

16 A. Good morning.

17 Q. Would you tell the jury and the Judge and the
18 court reporter, please, your full name and spell it for
19 them.

20 A. Certainly. My name is Kathryn Duesman.
21 Kathryn with a K, K-A-T-H-R-Y-N, Duesman, D-U-E-S-M-A-N.

22 Q. And where do you live?

23 A. I live in Pilot Point, Texas.

24 Q. Which is where?

25 A. Just north of Denton.

1 Q. Denton County?

2 A. It's actually going through the City of
3 Denton, and it's in the northeastern corner of Denton
4 County.

5 Q. Okay. So we've heard a little bit Friday --
6 excuse me -- and a little bit this morning about that
7 area and RTI being in a little place called Little Elm.

8 MR. CARROLL: Would you tell me how to
9 turn on my machine, or is it on?

10 Q. (By Mr. Carroll) Okay. Look up here at the
11 map, Ms. Duesman.

12 And there's a dot above Lewisville called
13 Little Elm. What's the significance of Little Elm,
14 Texas, to this lawsuit?

15 A. That's where the manufacturing facility is and
16 the headquarters of Retractable Technologies.

17 Q. That's -- that's all of us over here at this
18 table?

19 A. Yes, it is.

20 Q. Now you told the jury a second ago that you
21 live in a place called Pilot Point. Where is it?

22 A. It's just north of Little Elm. It's a smaller
23 town.

24 Q. Okay. And that's where you are?

25 A. Yes, sir?

1 Q. Is that about right?

2 A. Yes.

3 Q. Okay. Do you actually live in the city Of
4 Pilot Point?

5 A. Actually, I live right outside the city
6 limits.

7 Q. I told the jury earlier that you and your
8 husband have a farm and a ranch out there?

9 A. Yes.

10 Q. Is that how you-all earn your keep, so to
11 speak?

12 A. Yes. Yes, it is.

13 Q. Okay. How long have you and your family lived
14 up in the Pilot Point area?

15 A. I've lived there most of my life, and my
16 husband and I have been married for 27 years. So we've
17 been there all that time.

18 Q. Got children?

19 A. Yes, I do.

20 Q. Are they grown?

21 A. I hope so. They're --

22 Q. Let me ask it this way: Like Mr. Beck and I
23 talked about, were they at home this morning?

24 A. No. They're --

25 Q. Then they are grown as of today?

1 A. I hope.

2 Q. Okay. Okay. I told the jury a minute ago
3 that you are a 24-year experienced registered nurse.
4 Is that true?

5 A. Yes.

6 Q. Tell the jury a little bit about how you got
7 into that profession.

8 A. Well, I went to college at Texas Women's
9 University in Denton and became a nurse. Went right to
10 work at the county hospital in Denton, and that's
11 where -- that's where I worked. That's where I started
12 out working as a nurse in the obstetrical department.

13 Q. And you were involved, obviously, in patient
14 care?

15 A. Oh, yes. I took care of patients.

16 Q. Now, Ms. Duesman, the jury heard a little bit
17 on Friday about syringes and needles. Of course, that's
18 a lot of what the case is about.

19 A. Yes.

20 Q. True?

21 A. Yes.

22 Q. And I know this sounds kind of dumb, but I
23 assume you've given shots in your career.

24 A. Oh, yes, I have.

25 Q. And I'm assuming that when you were at nursing

1 university in Denton, you were trained about such.

2 A. Yes, I was.

3 Q. And the jury heard on Friday that one of the
4 issues that we're talking about in this case is how in
5 the world do you protect folks like you from contact
6 with contaminated needles.

7 You heard that?

8 A. Yes, I did.

9 Q. And you heard that we talked about a term
10 called needlestick injury.

11 A. Yes.

12 Q. When did you first hear that?

13 A. I first heard of that when I was in college
14 and certainly as a nurse working in a hospital, giving
15 shots.

16 Q. Okay. What did -- what did the folks there at
17 Texas Women's teach you in the early '80s about
18 needlestick injury and how to protect against them?

19 MS. PIROZZOLO: Objection, Your Honor.

20 THE COURT: Excuse me?

21 MS. PIROZZOLO: Objection.

22 THE COURT: What's the basis of the
23 objection?

24 MS. PIROZZOLO: Hearsay.

25 THE COURT: Overruled.

1 Q. (By Mr. Carroll) Go ahead.

2 A. They just taught us to be careful and to not
3 touch the needle. We would often recap needles to cover
4 them up, which was really kind of dangerous in and of
5 itself.

6 Q. Okay. I was going to borrow Mr. Beck's giant
7 needle, but I don't see it here today.

8 Did you bring some props, some needles for us
9 to look at?

10 A. Yes, sir. They're not as big as his, but...

11 Q. Okay. I am going to walk up here toward you,
12 with the Court's permission, or maybe I will get Mr.
13 Potts to help me out here.

14 Would you please, Ms. Duesman, find in that
15 box a sterile capped syringe and needle?

16 A. Yes, sir.

17 Q. Okay. And with the Court's permission --

18 MR. CARROLL: Your Honor, may she get up
19 and walk a little bit so the jury can see that? I was
20 hoping I could use Mr. Beck's big needle.

21 THE COURT: Yes, sir.

22 MR. CARROLL: Thank you, Your Honor.

23 Q. (By Mr. Carroll) All right. Just stop right
24 there, if you would.

25 A. (Complies.)

1 Q. Now, obviously the cap -- I think everybody on
2 the jury can see it.

3 A. Right there (indicates).

4 Q. And go ahead and take it off there, if you
5 would?

6 A. (Complies.)

7 Q. Now, that -- that needle is supposed to be
8 sterile, correct?

9 A. Yes.

10 Q. Now, I talked to the jury panel, before they
11 were lucky enough to get picked on Friday, about a term
12 that's called keeping your hand behind the sharp.

13 Have you ever heard that before?

14 A. Yes, I have.

15 Q. What does that mean?

16 A. That means you don't want to get any closer to
17 that needle with your hand as possible. So you want to
18 keep your hands back behind.

19 Q. Okay. And you mentioned to the jury a second
20 ago that you were taught that recapping a contaminated
21 needle is bad business, correct?

22 A. Yes.

23 Q. Why?

24 A. It's very dangerous. If you bring that cap
25 forward, you have a really good chance of sticking

1 yourself with that dirty needle. And if you do, you can
2 get sick.

3 Q. Okay. Now, Ms. Duesman -- thank you. You can
4 return to your seat, with the Court's permission.

5 A. (Complies.)

6 Q. Now, Ms. Duesman, what did you do after you
7 got licensed?

8 I think you told the jury you worked in a
9 hospital up there in Denton County, maybe helping them
10 deliver babies?

11 A. Yes, sir.

12 Q. At that point in the practice, the nursing
13 practice, was there any -- to your remembrance, was
14 there any kind of, quote, safe needle?

15 A. No.

16 Q. How did you all protect yourself as nurses
17 back in the '80s?

18 A. When I first started working at the county
19 hospital, we would give an injection in the patient's
20 room and usually recap the dirty needle and take it back
21 to the nurses' station.

22 And at that hospital, we usually had a needle
23 cutter, and we would actually cut the needles off, and
24 it was -- that was a long time ago.

25 Q. Not so long --

1 A. Well --

2 Q. -- to some of us.

3 A. And that's where you would dispose of it. But
4 that's -- that's what I did when I was right out of
5 school in '85.

6 Q. And that was -- was that the standard at that
7 time?

8 MS. PIROZZOLO: Objection, Your Honor.

9 MR. CARROLL: I withdraw that question.

10 Q. (By Mr. Carroll) That's how you were taught?

11 A. I should say that's how that hospital handled
12 their contaminated sharps.

13 Q. Okay. Now, what is a sharp box?

14 MR. CARROLL: By the way, do we have one?

15 Q. (By Mr. Carroll) Okay. Is this a sharp box?

16 A. Yes, it is.

17 Q. And I guess the purpose of this is pretty
18 obvious when you look at what's inside, right?

19 A. Yes.

20 Q. What's the purpose of a sharp box?

21 A. It's a puncture-resistant container to put
22 contaminated sharps in until after you've used them.

23 Q. Okay. Now, Ms. Duesman, I want to take you
24 forward a little bit from 1985, when you got your
25 license and hired on up there at the hospital in

1 Denton -- excuse me.

2 When did you first hear or learn about
3 so-called retractable needles?

4 A. The first time I ever saw the retractable
5 technology was on a local news story that was talking
6 about the fact that they were going to build a syringe
7 factory in Little Elm, which wasn't very far from my
8 home.

9 And I didn't even hear the name of the
10 company, but when I happened to look at the TV, I saw a
11 closeup of that technology and saw the needle disappear,
12 and I kind of wished they would do it again, because it
13 was really -- really pretty interesting and amazing to
14 me.

15 Q. And what happened after that?

16 A. Well, after that, I told my husband about it,
17 that they're building a syringe factory in Little Elm,
18 Texas. And he happened to be looking in the paper, the
19 local paper, and they had an ad looking for nurses to
20 come work for a company and train people on a new
21 technology.

22 Q. Now, wait a minute. I thought you had a job.

23 A. I did. I was working at the hospital nights.
24 By then, I had several little kids, so I worked during
25 the nighttime.

1 Q. Okay. Looking for a day job?

2 A. Always looking for a day job.

3 Q. So what happened?

4 A. Again, I didn't even know the name of the
5 company, but I was so interested in the technology, I
6 called the phone number and went down there to apply for
7 a job.

8 Q. And when you say you went down there, look up
9 here on the screen. Is this where you went?

10 A. That's where I went.

11 Q. Tell the jury a little bit about what that
12 building looked like back -- what year would this have
13 been, by the way?

14 A. That would have been in 1996.

15 Q. Thirteen years ago?

16 A. Yes, sir.

17 Q. And you drove, I guess -- where is this little
18 building or was it?

19 A. That little building is in Lewisville, Texas.

20 Q. Okay. And back to our little map, that's just
21 south of where you-all were, right?

22 A. Correct.

23 Q. Okay. And tell the jury a little bit about
24 what you -- by the way, did you go by yourself?

25 A. Yes.

1 Q. What did you find when you got there?

2 A. That little building, which honestly wasn't
3 very impressive. But I went in and filled out an
4 application, and they -- they showed me the syringe,
5 and, sure enough, it was the same one I had seen on TV
6 and --

7 Q. What was your reaction when you saw it?

8 A. I thought it was the safest way to give a
9 shot.

10 Q. Had you ever seen anything like it?

11 A. Never.

12 Q. Did you ask any questions about it?

13 A. Sure. Sure, I did.

14 Q. Like what?

15 A. The -- one of the first things I asked -- I
16 knew it was safe for giving a shot, but I asked how
17 patients felt about it, how did it feel to them.

18 Q. Did you get any reply from them without
19 getting into any detail about who said what?

20 A. No. They -- that said that patients reacted
21 well.

22 Q. Okay. Did you believe that?

23 A. I wanted to know for sure.

24 Q. How did you -- how did you test it out?

25 A. I asked if I could have a syringe to take with

1 me, and they told me I couldn't. But I came back for
2 another interview, and I guess I probably signed some
3 papers by then, and I -- they let me have a sterile
4 syringe.

5 And I still had my night job. I still wasn't
6 sure about all this, so I actually had a little vile of
7 sterile saline that I had, and I drew up some and I made
8 my husband let me give him a shot and --

9 Q. So he was the guinea pig?

10 A. Yes, he was.

11 Q. Well, did he live?

12 A. He lived.

13 Q. As a matter of fact, I think he's in the
14 courtroom. There he is right there (indicates).

15 A. Yes.

16 Q. Stand up and let's make sure you're still
17 alive.

18 Okay. He doesn't look too much worse for the
19 wear.

20 A. No, he did fine.

21 Q. Okay. Did you have any other concerns?

22 A. I asked if they -- if they had patented this
23 technology.

24 Q. What did you learn?

25 A. They said they had.

1 Q. Okay. Now, Ms. Duesman, that was way back in
2 198 -- I mean '96.

3 Did you hire on with them?

4 A. Yes, I did.

5 Q. Doing what?

6 A. Training nurses on the technology, training
7 them how to use it and how it worked.

8 Q. Are you still in that same job today?

9 A. Yes, I am. That's what I do. Not to maybe
10 people in different places, but that's what I'm still
11 doing.

12 Q. As a matter of fact, you've got global duties
13 today, do you not?

14 A. Yes, I do.

15 Q. I mean, like traveling overseas and whatnot?

16 A. Yes. But the trips are longer, but what I do
17 is pretty much the same.

18 Q. A long way from Pilot Point?

19 A. Yes. Yes, it is.

20 Q. All right. Let me show you another picture.
21 And what's this?

22 A. That's the manufacturing facility where they
23 make our syringes, our technology.

24 Q. Now, that is in Little Elm, right?

25 A. Yes, sir.

1 Q. How many folks work for our company?

2 A. About -- about 150.

3 Q. They're at Little Elm?

4 A. Yes.

5 Q. Is that where you go to work every day?

6 A. Actually, now I -- because I travel quite a
7 bit, I work from my home, and I go in frequently for
8 meetings and anything they need me for at the plant, at
9 the factory.

10 Q. Excuse me. Of course, we got a lawsuit
11 against our friends over here at B&D.

12 You know who they are?

13 A. Yes, I do.

14 Q. As I understand from Mr. Beck on Friday,
15 they're just three or four counties away in Bowie County
16 in Texarkana, correct?

17 A. No, I don't think so.

18 Q. Do they have a manufacturing facility in Bowie
19 County?

20 A. Not that I'm aware of.

21 Q. Do they have any employees that you know of in
22 Bowie County?

23 MS. PIROZZOLO: Judge?

24 THE COURT: Mr. Carroll?

25 MR. CARROLL: I was just trying to find

1 out a little bit about the opponent, Your Honor.

2 THE COURT: Well, if she knows, I will
3 allow her to answer. Overruled.

4 Q. (By Mr. Carroll) Do you know anything about
5 whether they, in fact, have any presence in the state of
6 Texas?

7 A. I don't know of any factories or anything like
8 that.

9 Q. Where are they?

10 MS. PIROZZOLO: Objection, Your Honor.

11 Q. (By Mr. Carroll) If you know.

12 A. Well, I know the headquarters are --

13 THE COURT: I'll overrule. I'll allow
14 her if show knows where the headquarters is located.

15 MR. CARROLL: Thank you, Your Honor.

16 Q. (By Mr. Carroll) Where do you know their
17 headquarters to be?

18 A. In New Jersey.

19 Q. Where is your headquarters?

20 A. In Little Elm, Texas.

21 Q. Okay. Based on your experience as a
22 registered nurse, was there a point in your career where
23 the federal government got involved in needlestick
24 injuries?

25 A. Yes.

1 In 1991, they -- the federal government, OSHA,
2 the Occupational Safety and Health Administration,
3 issued regulations.

4 Q. Let me stop you right there.

5 How do you know that?

6 A. I -- I know it because it changed the way we
7 did things in hospitals.

8 Q. You as a -- as a patient-care nurse at that
9 point?

10 A. Yes, sir.

11 Q. Okay. And did -- did you learn that on the
12 job, so to speak, that the rules had changed?

13 A. Well, actually, the regulation was issued in
14 1991. I actually was home. I had just had a baby, so I
15 had quit work for a little while, and I came back in
16 '92.

17 And just the way you handled contaminated
18 sharps was a lot different, and there were different
19 policies that you needed to do at the hospital.

20 Q. Did OSHA change the way you dealt with these
21 boxes?

22 A. Yes.

23 Q. How so?

24 A. No more cutting needles. That was gone. And
25 you weren't to be recapping any needles, ever. And they

1 actually -- part of the -- part of the regulations were
2 that those sharps boxes were at the point of use. So
3 you didn't have to use them and walk down the hall to
4 put them away. They would be right there at the
5 patient's bedside, for example.

6 Q. Okay. Ms. Duesman, I've written on my
7 chalkboard here the phrase, minimize or eliminate, and
8 then I put in red, exposure to contaminated needles.

9 A. Yes.

10 Q. Is this -- is this the first time you've heard
11 that phrase?

12 A. Oh, no. That -- that is in the OSHA
13 regulations. Actually, I think what it says is you must
14 minimize or eliminate the exposure to contaminated
15 sharps --

16 Q. Okay.

17 A. -- which is the same as needles.

18 Q. I'm going to get it right, so I'm going to
19 scratch out needle and write in sharps.

20 I have written in the term, exposure. Why are
21 they talking about exposure?

22 A. My understanding of the regulations is they
23 don't -- they don't want healthcare workers to even be
24 exposed to the contaminated sharp or to minimize, at the
25 bare minimum, any exposure to prevent a needlestick

1 injury.

2 Q. That was back in '91?

3 A. Yes.

4 Q. Did the government get into the business of
5 telling manufacturers, such as B&D and RTI, how to make
6 a safer needle?

7 A. No.

8 Q. After 1991, you, as a practicing registered
9 nurse before '96 when you saw Mr. Shaw's technology, did
10 you see any attempts out in hospitals and doctors'
11 offices and whatever by industry to comply with
12 eliminating the exposure to contaminated sharps?

13 A. Well, I -- I did see the change in the
14 location of sharps boxes. I did see some changes in
15 some of the IV systems. I didn't see any different
16 syringes at that time.

17 Q. Okay. Did you ever hear of a law that was
18 passed in 2000 called the Needlestick Prevention Act?

19 A. Yes.

20 Q. What was that all about, from your experience
21 as a registered nurse?

22 A. That was a law -- my understanding of the law
23 that was passed that really made an emphasis on new
24 technologies to eliminate that, to eliminate the
25 exposure that we talked about. And it broadened up the

1 regulations. It made them a little bit more specific.
2 It also had different components in that. And it was --
3 actually, that law revised those OSHA regulations. So
4 they issued those OSHA regulations in 2001 right after
5 the law to -- to reflect that they broadened what the
6 terms meant. They made it a little more specific.

7 Q. For instance, did the government specify that
8 it was a no-no to recap a dirty needle?

9 A. Yes. Yes.

10 Q. For the reasons that you just told the jury?

11 A. Yes, sir.

12 Q. Now, Ms. Duesman, comes the fun part. I want
13 you -- with the Court's permission, I want you to give
14 me a shot. Not a real shot.

15 Do you have your --

16 A. Yes, I do.

17 Q. -- pad?

18 MR. CARROLL: Your Honor, may she come
19 down and I join her over here on the side?

20 By the way, I'd be glad for anybody here
21 to take a shot.

22 MR. BECK: Is it a real shot?

23 Q. (By Mr. Carroll) Okay. Now, here is what I
24 would ask you to do, Ms. Duesman, with Judge Folsom's
25 permission: I want you to show the jury what we have

1 here.

2 Got a pad, right? That's the one I used on
3 Friday.

4 What else do we have?

5 A. Well, I have a standard syringe and the
6 retractable.

7 Q. Okay. When you say standard syringe, what do
8 you mean by standard?

9 A. This syringe doesn't have any safety feature.

10 Q. Okay. So once we uncap this one and give a
11 shot and make it contaminated, then there's no
12 protection, so to speak?

13 A. Yes.

14 Q. Okay. And then what's this over here?

15 A. This is the VanishPoint syringe.

16 Q. Mr. Shaw's technology over here?

17 A. Yes.

18 Q. Okay. Okay. So let's -- lead us the way.

19 Show me how -- I get a shot. And I'll tell
20 you I haven't had one in a while.

21 A. Okay.

22 Q. So I'm not too pleased about this. Okay.

23 A. Okay.

24 Q. I'm going to -- I'm going to move over here so
25 the jury can see.

1 Tell the jury what you're doing to start with.

2 A. Okay. If I was giving an injection, of
3 course, first I'd wipe the site with alcohol.

4 You're making it hard for me to --

5 Q. Well, tell me what I can do to make it easier.

6 A. Then I would take my syringe, which I probably
7 would have already filled up with medication.

8 Q. Okay.

9 A. I'd give my injection and push the medication
10 in.

11 Q. By the way, it didn't hurt at all.

12 A. And then I'd pull the needle out, and then I
13 would hold the site, because people bleed a little bit
14 after that.

15 Q. Well, what are you going to do with that dirty
16 needle?

17 A. Well, I am kind of in a fix now, because the
18 sharps box is far away, so I -- I would have to set it
19 down probably.

20 Q. Now, that's not a good idea.

21 A. No, it's not.

22 Q. What about me?

23 A. Well, I need to put a Band-Aid on you.

24 Q. Okay.

25 A. So I need to take care of that, and then I

1 would have to get to a point where I could put this into
2 a sharps container.

3 Q. Okay. But it's dangerous right now.

4 A. Well, yes, at this point, it's contaminated.

5 Q. Okay. All right. So that was the old way?

6 A. Yes.

7 Q. All right. Why don't you recap that baby,
8 even though we're not supposed to do that.

9 By the way, is it a good idea to reuse
10 needles?

11 A. No.

12 Q. I mean, that's kind of a dumb question. I
13 think everybody knows that.

14 What about reusing the actual syringe?

15 A. No. That would be dangerous.

16 Q. Show the jury the difference between the
17 needle and the syringe while we're standing here.

18 A. This is the needle portion, and this is the
19 syringe portion (indicates).

20 Q. All right. Now, if you would, put the needle
21 down.

22 A. (Complies.)

23 Q. If it were just that in your right hand, just
24 the syringe, that doesn't have any sharp to it, does it?

25 A. No.

1 Q. Okay. What if we were able to make the needle
2 disappear into that syringe?

3 A. It would be a lot safer.

4 Q. Okay. Show the jury why using Mr. Shaw's
5 technology.

6 A. Oh, certainly.

7 Q. I may need a real shot.

8 A. Same process. I would get the site prepared.

9 Q. Let's scoot right down here so everybody can
10 see what we are so proud of.

11 A. I would never give a shot to someone standing
12 up, by the way.

13 Q. You're fine.

14 A. I would give my injection, inject my
15 medication.

16 Q. And it popped.

17 A. And now the needle is back inside the syringe.

18 Q. Why -- why, now, is this one like -- what is
19 the difference between these two?

20 A. This one has been used.

21 Q. Well, I understand, but what's it got inside
22 of it?

23 A. Oh, they are both contaminated. I mean, this
24 one has the contaminated sharp all enclosed inside the
25 syringe; this one, we took the needle off.

1 Q. So let's go back to our real-world example.
2 Here I am with my arm bleeding, and you've just finished
3 up giving me my shot with Mr. Shaw's invention.

4 Now what do you do?

5 A. Well, I -- it would actually be easy for me to
6 set that down, put a Band-Aid on, and then put that in
7 the sharps container.

8 Q. Is that going to hurt anybody now?

9 A. No.

10 Q. Why not?

11 A. The sharp is -- the dirty needle is all
12 enclosed inside the syringe.

13 Q. Okay. One other question.

14 A. I'm through.

15 Q. That's good. And that didn't hurt at all.

16 Thank you. Here's that.

17 The Shaw technology that you show every day of
18 your working life, does it allow for a reusable needle?

19 A. No.

20 Q. How -- how does it prevent that?

21 A. Because when the medication is injected, when
22 the plunger's fully depressed, the needle retracts
23 inside, and there's no way to reuse it.

24 Q. Okay. Now, on Friday, Mr. Beck showed the
25 jury a picture of a lot of BD's safety products, and a

1 fair number of them had some kind of what I call an
2 external device, like a sheath or a shield or a tube, to
3 go around the dirty needle.

4 Have you seen products like that?

5 A. Yes, I have.

6 Q. How many hands do you have to have to
7 manipulate that kind of a safety product?

8 A. Well, I guess about three, because if you're
9 taking care of your patient and taking care of that
10 patient you just gave an injection to, it still would
11 take two hands to, for example, to push a sheath forward
12 on that.

13 Q. And when you get done with that kind of safety
14 idea, are you doing anything different, really, than
15 recapping?

16 MS. PIROZZOLO: Objection, Your Honor.

17 THE COURT: Based on what?

18 MS. PIROZZOLO: Foundation.

19 THE COURT: Mr. Carroll, why don't you
20 establish a foundation?

21 MR. CARROLL: Thank you, Your Honor.

22 Q. (By Mr. Carroll) Based on your experience,
23 you've told the jury that recapping is dangerous and
24 against the law.

25 Are these external sheaths where you have to

1 manipulate them, any different in your experience than
2 recapping?

3 MS. PIROZZOLO: Objection, Your Honor.

4 THE COURT: Overruled.

5 A. No. It's covering up a dirty needle.

6 Q. (By Mr. Carroll) Okay. How is the Shaw
7 invention different in your experience? I know you're
8 not -- you're not an engineer.

9 A. No, I'm not.

10 Q. Well, congratulations.

11 From your experience and your understanding as
12 a nurse who actually uses the Shaw technology, how is it
13 different from covering up a dirty needle?

14 A. The big difference is that it just
15 automatically takes that needle out of the way.

16 There's -- it comes right from the patient,
17 goes right into that syringe, so you never get exposed
18 to it at all. You never have to take the needle out and
19 be exposed to that dirty sharp even for an instant.

20 Q. Mr. Beck told the jury on Friday that some
21 nurses like to be able to change a needle from one
22 syringe to another syringe.

23 Is that possible with the Shaw technology?

24 A. No, it's not.

25 Q. Why not?

1 A. Because the needle is built into the syringe.

2 Q. Is that a problem for you as a 24-year
3 practicing nurse?

4 A. No.

5 Q. Why not?

6 A. Because it's unnecessary to do, and there's
7 actually some risks. If you take that needle off, there
8 is a risk that the syringe or the needle or the
9 medication inside can become contaminated.

10 And there have been organizations like the
11 CDC, the Centers for Disease Control, that has said it's
12 not necessary.

13 Q. Have you ever heard the term closed system,
14 closed system insofar as giving shots?

15 A. Yes. The term, closed system, is used really
16 in a lot of medical devices or technologies, because the
17 more you can keep it closed, the less risk there is for
18 it to get contaminated, to get some kind of bacteria on
19 it that could harm the patient.

20 Q. Make somebody sick for years later?

21 A. Yes.

22 Q. Ms. Duesman, I told the jury that you and your
23 husband kind of voted with your pocketbook.

24 Is that true?

25 A. Yes, we did.

1 Q. Do you own shares or stock in Retractable
2 Technologies Inc.

3 A. Yes, I do -- yes, we do.

4 Q. So you've got a horse in this race, so to
5 speak?

6 A. Yes.

7 Q. Are you telling -- have you told the jury
8 anything today that you don't tell people every day of
9 your professional life?

10 A. No.

11 Q. I mean, this is what you do for a living.

12 A. Yes, it is.

13 Q. Do you believe in your product?

14 A. Absolutely.

15 Q. Today, does the industry still put out
16 dangerous needles?

17 A. Yes.

18 Q. The ones just like you gave my first shot
19 with?

20 A. Yes.

21 Q. About how many?

22 A. Millions and millions.

23 Q. Thank you, ma'am.

24 MR. CARROLL: I pass Ms. Duesman, Your
25 Honor.

1 THE COURT: Cross-examination.

2 CROSS-EXAMINATION

3 BY MS. PIROZZOLO:

4 Q. Good morning, Ms. Duesman.

5 A. Good morning.

6 Q. You are the corporate representative of RTI
7 here today?

8 A. Yes.

9 Q. And that means you are only appearing here on
10 behalf of the corporation?

11 A. Yes.

12 Q. Okay. And you've been at RTI since 1996, you
13 said?

14 A. Yes.

15 Q. And you're a stockholder in the company?

16 A. Yes.

17 Q. Now, you're a registered nurse, correct?

18 A. Yes.

19 Q. And your work at RTI has focused on the
20 clinical aspects of the VanishPoint syringe, correct?

21 A. Yes.

22 Q. And your testimony here today has focused on
23 the clinical aspect of the VanishPoint syringe, correct?

24 A. Yes.

25 Q. But you've said, I think on your direct, that

1 you're not an engineer; is that right?

2 A. No, I am not.

3 Q. Okay. And you didn't design the retraction
4 mechanism in the VanishPoint syringe, correct?

5 A. No, I did not.

6 Q. And you're not an inventor on the patents
7 being asserted in this case; is that right?

8 A. That's correct.

9 Q. Okay. Mr. Shaw is the sole inventor on those
10 patents; is that right?

11 A. Yes.

12 Q. And this is a patent infringement case,
13 correct?

14 A. Yes.

15 Q. And in this case, RTI is accusing Becton
16 Dickinson of infringing three patents, correct?

17 A. Yes.

18 Q. But in your direct testimony, you didn't
19 discuss any of the three patents at issue in this case,
20 correct?

21 A. That's correct.

22 Q. Okay. You didn't discuss the specific claims
23 of those patents that RTI is asserting against Becton
24 Dickinson, correct?

25 A. That's correct.

1 Q. And you didn't discuss the type of retraction
2 mechanism that is claimed in those patents, correct?

3 A. Yes.

4 Q. Now, the BD products accused of infringement
5 here today are the 3ml Integra and the 1ml Integra,
6 correct?

7 A. Yes.

8 Q. But during your testimony, you didn't discuss
9 the retraction mechanism of those two syringes, correct?

10 A. Yes.

11 Q. And, in fact, you don't know how the
12 retraction mechanism of those syringes work, correct?

13 A. I'm not an engineer, so I don't have a
14 complete understanding of that.

15 Q. So in this case, the jury is going to be asked
16 to decide whether the BD products infringes the RTI
17 patents, correct?

18 A. Yes.

19 Q. And you really can't shed any light on that,
20 can you?

21 A. No. That's -- that's not what I'm here for.

22 Q. And you aren't familiar with other retractable
23 syringes that existed in patents before Mr. Shaw filed
24 his patent in this case, correct?

25 A. That's correct.

1 Q. So you can't really shed any light on the
2 issue of whether Mr. Shaw's patents are valid in light
3 of the prior art, correct?

4 A. That's correct.

5 Q. Now, you talked earlier about how the
6 VanishPoint works. You activate the retraction
7 mechanism in the patient, correct?

8 A. Correct.

9 Q. Okay. So if the VanishPoint is operated as
10 recommended, the nurse or clinician fully depresses the
11 plunger while the syringe is in the patient, correct?

12 A. While the needle is in the patient.

13 Q. The needle is in the patient.

14 A. Yes.

15 Q. Thank you.

16 Now, the Integra syringes can be activated in
17 or out of the patient, correct?

18 A. My understanding is that is -- that's on the
19 instructions for use.

20 Q. Okay. The instructions are that the clinician
21 can operate the retraction mechanism in or out of the
22 patient, correct.

23 A. Yes.

24 Q. Okay. So if clinicians want to operate the
25 retraction mechanism out of the patient, they have the

1 option to choose Integra, correct?

2 A. I'm sorry. I don't know that I understand
3 that really well.

4 The instructions say they can do it either
5 way, so...

6 Q. And so --

7 A. So they could choose that.

8 Q. -- Integra gives them that choice, correct?

9 A. Yes.

10 Q. And VanishPoint doesn't, correct?

11 A. No.

12 Q. Now, you talked about the attached needle in
13 the VanishPoint syringe, correct?

14 A. Yes.

15 Q. So clinicians can't remove the needle from the
16 VanishPoint syringe?

17 A. Correct.

18 Q. Okay. In contrast, BD's Integra 3mL syringe,
19 you can detach the needles from the syringe, correct?

20 A. Yes.

21 Q. And RTI hasn't done any study to determine
22 whether detachable -- customers prefer detachable
23 needles, correct?

24 A. No.

25 Q. Now, you talked a little bit about other

1 syringes on the safety market, correct?

2 A. Yes.

3 Q. VanishPoint competes with those syringes,
4 correct?

5 A. Yes.

6 Q. Okay. It competes with the BD Integra; is
7 that right?

8 A. Yes.

9 Q. It competes with the BD SafetyGlide, correct?

10 A. Yes.

11 Q. It competes with the BD Eclipse safety
12 product, correct?

13 A. Yes.

14 Q. It competes with the BD safety lock product,
15 correct?

16 A. Yes.

17 Q. It competes with -- against all the safety --
18 different types of safety syringes that are on the
19 market, correct?

20 A. Yes.

21 Q. So that means sometimes customers choose other
22 safety products over VanishPoint, correct?

23 A. Yes.

24 Q. And those are all safety products that are
25 approved by the FDA; is that right?

1 A. Well, the standards are approved by the FDA,
2 but, yes, they are.

3 Q. So the FDA has determined that those products
4 are safe and effective, correct?

5 A. I'm not sure that the FDA determines whether
6 they prevent needlestick injuries, but the FDA has
7 permitted them to be marketed.

8 Q. The FDA has approved those products for use --

9 A. For use --

10 Q. -- by clinicians in this country --

11 A. Yes.

12 Q. -- correct?

13 A. Yes.

14 Q. Now, you talked about RTI's manufacturing
15 facilities in Little Elm; is that right?

16 A. Yes.

17 Q. RTI has manufacturing facilities elsewhere,
18 correct?

19 A. Yes.

20 Q. Okay. Where -- where are the other
21 manufacturing facilities?

22 A. We have another contract manufacturer in
23 China.

24 Q. Okay. And what percentage of RTI's syringes
25 are manufactured in China?

1 A. I don't know. I'm really not sure.

2 Q. Now, Ms. Duesman, you're familiar with the
3 ECRI organization?

4 A. Yes.

5 Q. Okay. And that is a nonprofit organization
6 that evaluates medical devices, correct?

7 A. Yes.

8 MS. PIROZZOLO: And I want to put up on
9 the slide projector --

10 Q. (By Ms. Pirozzolo) And I can give you a copy
11 of an ECRI report.

12 THE WITNESS: Thank you.

13 Q. (By Ms. Pirozzolo) Now, in August of 2007,
14 ECRI issued a report on needlestick prevention devices,
15 correct?

16 A. Yes.

17 Q. And in that report, ECRI rated the BD Integra
18 product, correct?

19 A. Yes.

20 MS. PIROZZOLO: Can we go to that page,
21 please.

22 Q. (By Ms. Pirozzolo) And ECRI evaluated the BD
23 Integra product, correct?

24 A. Yes.

25 Q. And ECRI rated the BD Integra product

1 preferred; is that right?

2 A. Yes.

3 Q. Okay. And in the report, ECRI stated that the
4 BD Integra product offered excellent protection against
5 needlesticks, correct?

6 A. Yes.

7 Q. And is easy to use, correct?

8 A. Correct.

9 Q. Okay. Now, VanishPoint is not a
10 hundred-percent effective, correct?

11 A. If it's activated in the patients and then
12 retracted, there's no way you can be exposed to it.

13 Q. But needlesticks have occurred with the
14 VanishPoint syringe, correct?

15 A. Yes.

16 MS. PIROZZOLO: I have no further
17 questions.

18 THE COURT: Redirect?

19 MR. CARROLL: Just briefly, Your Honor.

20 REDIRECT EXAMINATION

21 BY MR. CARROLL:

22 Q. I want to ask you about that study that we
23 were just looking at.

24 MR. CARROLL: Ms. Martin, can you turn me
25 on?

1 Q. (By Mr. Carroll) We just got -- you just
2 talked about this study, and over here it says top
3 choices, BD and RTI. But I want you to look down here
4 where it says not good choices.

5 Any of our products listed on not good
6 choices?

7 A. No, sir.

8 Q. Any of BD's listed on not good choices?

9 A. Yes.

10 Q. BD safety lock syringe, and the document that
11 the BD lawyer just asked you about says: We don't
12 advise the purchase of these products, all of which use
13 barrel shields.

14 A. That's correct.

15 Q. Do they still sell those things?

16 A. Yes.

17 Q. Is that one of the products that Mr. Beck
18 showed the jury on Friday, bragging about his company?

19 A. Yes.

20 Q. And the very document that the BD lawyer asked
21 you about says don't buy this, and they still sell it?

22 A. Yes.

23 Q. I want to ask you -- excuse me -- one last
24 question.

25 Do you have one of your props there?

1 MR. CARROLL: Your Honor, may I come
2 around?

3 THE COURT: Yes.

4 MR. CARROLL: Thank you.

5 THE COURT: You don't necessarily have to
6 ask permission. I know it's a --

7 MR. CARROLL: Old habits die hard, Judge.

8 Q. (By Mr. Carroll) Let me have a syringe and a
9 needle, just the one that's --

10 A. Which one?

11 Q. -- unguarded, so to speak.

12 A. Sure.

13 Q. Now, you were asked a question about the
14 difference between the accused retractable and our
15 patented technology. And I think you testified that
16 they advise -- that they said that you could activate it
17 in or out of the patient.

18 A. Yes.

19 Q. That's theirs, the one we're suing, correct?

20 A. Correct.

21 Q. Now, ours you can't activate, other than in
22 the patient when you finish giving the shot, correct?

23 A. When you -- when you finish giving the shot,
24 it automatically activates.

25 Q. It's automatic. Part of the shot?

1 A. Correct.

2 Q. Here's my question: What possible sense does
3 it make to you, as a 24-year practicing nurse, that you
4 would tout as a safety feature anything that allowed you
5 to come out of a patient's body with a dirty needle?

6 A. None.

7 Q. What sense does that make?

8 A. None.

9 Q. And they brag on that, right?

10 A. Yes.

11 Q. Okay. That's all I have. Thank you, ma'am.

12 THE COURT: Recross.

13 RECROSS-EXAMINATION

14 BY MS. PIROZZOLO:

15 Q. Just one question.

16 MS. PIROZZOLO: Dennis, could you go to
17 Page 240 of Exhibit -- Plaintiff's Exhibit 264?

18 Could you focus in on the top of the
19 right-hand column where it says also good candidates?

20 Q. (By Ms. Pirozzolo) Also, good candidates,
21 Ms. Duesman, do you see the BD Eclipse needle rated as a
22 good candidate by RTI -- I mean, ECRI?

23 A. Yes.

24 Q. And the BD safety slide -- SafetyGlide syringe
25 is rated as a good candidate by ECRI, correct?

1 A. Yes.

2 MS. PIROZZOLO: No further questions.

3 MR. CARROLL: No further questions.

4 THE COURT: You may step down.

5 Call your next witness.

6 MR. BOWLES: With the Court's permission,

7 Plaintiff calls Mr. Neil Sheehan.

8 THE COURT: If you'll please come around.

9 COURTROOM DEPUTY: If you'll raise your
10 right hand.

11 (Witness sworn.)

12 NEIL SHEEHAN, PLAINTIFF'S WITNESS, SWORN

13 DIRECT EXAMINATION

14 BY MR. HARDIN:

15 Q. Good morning, Mr. Sheehan.

16 A. Good morning, sir.

17 Q. Could you please state your full name and
18 current occupation for the record?

19 A. My name is Neil Sheehan, N-E-I-L,
20 S-H-E-E-H-A-N, and I'm a consulting engineer in the
21 field of medical devices.

22 Q. What's your educational background,
23 Mr. Sheehan?

24 A. I have a Bachelor of Science in mechanical
25 engineering from Villanova University from 1968. I

1 graduated with the highest honors, summa cum laude. I
2 did some graduate work at Harvard, and later on, did
3 some additional work at the University of California in
4 organic -- organic chemistry and biology.

5 Q. And you said you're a consultant in the
6 medical device field, sir?

7 A. That is correct.

8 Q. How long have you been working in the medical
9 device field?

10 A. A little over a third of a century. About 34
11 years.

12 Q. And are you a member of any professional
13 associations, sir?

14 A. Yes. I am a senior member in the Society of
15 Plastics Engineers.

16 Q. What -- just for folks that may not have heard
17 about the Society of Plastics Engineers? Can you tell
18 what that society's interest is?

19 A. The society's interest is plastics, just like
20 in that film The Graduate in the '60s.

21 And so we concern ourselves with plastics, how
22 they're made, how they're used, et cetera. My
23 particular concern is how they're used in the medical
24 device field.

25 Q. What does a consulting engineer do in the

1 medical product field?

2 A. Well, speaking for myself, I do -- I do a
3 number of things. Sometimes I'll be asked by a company
4 to come in and design something from scratch.

5 Gee, we need a new syringe design. We need a
6 new IV set. We need a new dialysis device. We need a
7 new defibrillator. And then I'll come in and I'll help
8 design that from scratch from the very beginning.

9 And then other times I'm brought in because
10 they're having problems with their products. It doesn't
11 work. They can't manufacture it. And perhaps I can
12 figure out ways to help them manufacture it better,
13 help improve the performance, and make it a better --
14 better product.

15 And other times I'm asked to come for
16 startups, and this is one of the pleasures of being a
17 senior member of my group is, I get to help young folks
18 start companies. I do that for free and help them --
19 help them get going. It's kind of fun.

20 Q. Now, do you often make yourself available as
21 an expert witness in pieces of litigation like this that
22 deal with medical technology?

23 A. Yes, I do, sir.

24 Q. You mentioned that sometimes you help a
25 company who had developed a product figure out a way to

1 manufacture it.

2 If the product's already designed, I mean, if
3 we already have a drawing, it's all set up, why would
4 they need any assistance from you? I mean, if it's
5 all -- if it's all set up and the drawings are on the
6 boards?

7 A. That's a very good question. Just because you
8 can draw it does not mean you can make it, and that's
9 especially true when it comes to plastic things.

10 What you need to know and especially a process
11 called injection molding -- it's how this cup is made.
12 They squirt molten plastic into a mold, and then it
13 cools and out pops this -- actually, out pops a lot of
14 them (indicating).

15 And so -- I forgot the -- I'm sorry. I forgot
16 the beginning of the question.

17 Q. Why would they need your assistance?

18 A. I'm sorry. I'm just spacing out here. Excuse
19 me a second.

20 Q. If we have a drawing for that --

21 A. Oh, right, the drawing. I'm sorry.

22 Q. -- and I have a drawing for the cup and I'm
23 the manufacturer of the cup, why would I need to come
24 talk to you about it?

25 A. Sorry. Little claustrophobia.

1 Just because you can draw it does not mean
2 that you can make it. And so you can draw something
3 that's impossible to make. You, for instance, can draw
4 a ball, a tennis ball, and say, okay, look, I've drawn
5 this tennis ball. I have an outside and an inside.

6 And then -- but there's no way to mold that.
7 There's no way to have steel on the inside of the ball
8 and steel on the outside of the ball and then be able to
9 remove the steel.

10 So one must be very careful in how one --
11 that's a very simple example, but a lot of the patents
12 that are out there have designs that simply cannot be
13 made either because they can't be molded or they can't
14 be assembled.

15 And if they can be, it's going to be expensive
16 and difficult and a problem.

17 Q. What is your experience with molding
18 technology?

19 A. Oh, goodness. I've been involved with molding
20 plastic parts in the medical device field since day one
21 in my experience with the medical device field. So that
22 would be for 34 years.

23 Q. Now, we're going to talk about, in this case,
24 quite extensively the terms friction and clamping, but
25 I'm going to use a different term --

1 A. Sure.

2 Q. -- for you and ask you if you find any
3 relation to those terms that we're going to talk a lot
4 about in this case.

5 Can you tell the jury what a press fit is?

6 A. A press fit, which is also known as an
7 interference fit, is when you take something that's
8 larger than -- you take a shaft -- it's like a cork in a
9 wine bottle. You have an object that's larger being
10 pressed into a smaller hole. Sometimes this is done
11 with metal, and sometimes it's done with plastic.

12 So the idea is, you're pushing in a cork or a
13 rod that's larger than the hole it's going into. So as
14 a consequence, the part that's on the inside is all
15 scrunched and it's kind of pushing out, and the part on
16 the outside is feeling kind of intruded upon and it's
17 pushing back in, and that's what is known as an
18 interference fit.

19 And what holds that from coming out is
20 friction. And that's what press fit is.

21 Q. Now, when you have a press fit, do the
22 surfaces have to be completely smooth?

23 A. Ideally -- ideally, you would like them that
24 way, but no. From time to time, there will be bumps,
25 rings, and other features inside, but the primary -- the

1 essence of what's holding the two parts together is the
2 interference fit, and that leads to the friction, which
3 holds it together.

4 Q. Now, you mentioned to the jury that you have
5 done engineering work in the medical device field. And
6 this is a patent case.

7 A. Yes.

8 Q. Do you -- do you have any experience in
9 patenting or patents?

10 A. Yes. Excuse me. I'm the named inventor on 37
11 medical device patents.

12 Q. So are you sole inventor on those, co-inventor
13 on some?

14 A. Some sole inventor; some co-inventor.

15 Q. Okay. So in this patent case and from a
16 technology standpoint, is this case about what holds the
17 needle in the projected position before the spring
18 pushes it back, or is it about the thing that releases
19 it?

20 A. It's about what holds it in place, not what
21 releases it.

22 Q. And just broadly, what is required about how
23 the needle gets released, how the spring shoves the
24 needle back into the syringe?

25 A. The only thing that's required is that the

1 friction or clamping that's holding the needle -- the
2 needle in the -- the needle holder in the upright
3 position, the only thing that's important is that that,
4 in fact, is released, thus allowing the needle to
5 retract and the retainer member to -- to not retract.
6 That's the non-retractable part.

7 Q. And we'll get into some detail --

8 A. Sure.

9 Q. -- just in a moment, but do you have an
10 opinion as to whether or not BD syringes work that way?

11 A. Do they work which way?

12 Q. By a release of the friction from clamping or
13 friction that's holding the needle in a projected
14 position.

15 A. They do, sir.

16 Q. Is that true for both products? We've accused
17 both products. We've accused a small one called the 1ml
18 and a larger one called a 3ml.

19 A. That's correct.

20 Q. And does that fact meet at least some of the
21 requirements of the claims that define Mr. Shaw's
22 patented inventions?

23 A. Yes, sir.

24 Q. Are there other requirements of those claims?

25 A. Yes. Each claim consists -- and these are at

1 the back of the patents. These are the numbered
2 sections or sentences. They're really very long,
3 run-on sentences.

4 Each of those sentences or claims consist of a
5 number of separate limitations, and that fully describes
6 what the invention is. And that's what you compare the
7 accused product to to determine whether or not there is
8 infringement.

9 Q. Okay. I want to give now sort of an overview
10 for the jury of what you were asked to do in this case.

11 You were asked to come here by my client,
12 Retractable Technologies, Inc., and did you form
13 opinions, at our request, which you could share with the
14 jury in this case?

15 A. Yes, I did.

16 Q. Okay. What were those opinions that you
17 formed?

18 A. I was asked to form opinions regarding whether
19 or not the 1ml and 3ml Integra syringes infringed a
20 number of claims. There are three patents, and a number
21 of claims from each patent are being asserted.

22 I was also asked to look at the issue of
23 validity. Are these claims valid as issued? The Patent
24 Office issues them, and they're presumed valid, but BD
25 is free to argue that they're not.

1 So I took a look at that issue, and I found
2 them to be perfectly valid without a doubt.

3 And then I was also asked to look at the issue
4 of copying, whether or not BD copied Mr. Shaw's and
5 RTI's designs.

6 And I think those are the three primary areas.

7 Q. And, again, broadly -- we're going to look at
8 specifics, but what information did you review in order
9 to form those opinions?

10 A. Oh, well, to form those opinions, I had to
11 look at the accused products. I had to look at all --
12 at a number of the 1ml syringes, a number of the 3ml
13 syringes.

14 I also looked at dozens and dozens of drawings
15 associated with those products that were supplied by
16 Becton Dickinson so I could see all the little
17 dimensions that were in there, not just the ones that I
18 could measure on the outside.

19 I also looked at the patents, the three
20 patents-in-suit, read every word very many times, and
21 looked through all the claims, looked at all the prior
22 art that's cited on the face of the patent.

23 And that's the prior art -- and that can be
24 patents or it can be publications -- that were either
25 presented to the Patent Office or the Patent Office

1 found on its own and -- and looked at before granting
2 the patent, before granting the claims in that -- in
3 that patent.

4 So I looked at all the prior art. I looked at
5 all the prior art asserted by BD against these claims.

6 Of course, I looked at RTI syringes, but I --
7 you know, I had known about those.

8 Q. Any internal documents from Becton Dickinson?

9 A. Oh, in addition to the drawings, there are a
10 number of memos and guide -- excuse me -- memos and
11 guidelines and engineering documents beyond just
12 drawings about these products.

13 Q. Now, do you have an opinion of whether or not
14 the -- the main issue in the case is whether or not
15 these two infringing products -- excuse me.

16 Do you have the sample products up there,
17 samples of the BD products?

18 A. I do. I have a 1ml --

19 Q. Okay.

20 A. -- and the 3ml.

21 Q. Okay. So let's start with the 3ml. Can you
22 open that up and hold it up so the jury will know
23 exactly what we're accusing?

24 A. Sure. (Complies.)

25 Q. Have you formed an opinion, by comparing the

1 structure of that device to Mr. Shaw's patent claims
2 here, as to whether or not that device falls within the
3 description of Mr. Shaw's patent claims?

4 A. Yes, I've done that analysis, and it does.

5 Q. Okay. And what about the 1ml, the smaller
6 one?

7 A. Okay. This is a 1 milliliter, also known as a
8 1ml. Sometimes it's called a 1cc, which is a cubic
9 centimeter. A milliliter is a cubic centimeter of
10 water, so they're interchangeable. You'll hear cc and
11 ml.

12 Anyway, this is the -- this is the Integra
13 1mL.

14 Q. And did you form an opinion about whether or
15 not that product -- as it's structured from looking at
16 the drawings and your study of it, whether that product
17 also falls within the claim language, the definition of
18 claims that are contained in Mr. Shaw's patents?

19 A. Yes. I did a similar study for this one,
20 compared it to the claims that are being asserted
21 against the 1ml syringe, the 1ml Integra syringe, and
22 found this, too, to infringe.

23 Q. Did you form an opinion, from reviewing the BD
24 documents, as to whether or not you believe that BD
25 engineers copied features of Mr. Shaw's inventions into

1 those products?

2 A. Yes. It is my belief that BD engineers copied
3 features from Mr. Shaw's inventions into those two
4 products.

5 Q. Okay. And finally, in review of the BD
6 documents, did you see any documents containing opinions
7 from BD lawyers that asserted that the patents are
8 invalid or not infringed?

9 A. I don't recall seeing any such document.

10 Q. Okay. Now, before we go back to what the main
11 part of this case is, which is going to be this
12 comparison of each of these pieces of property called
13 claims to each of those devices, as sort of a background
14 so -- before we get there, you said you studied
15 Mr. Shaw's patent in depth?

16 A. Yes, all three of them.

17 Q. Okay. And can you give the jury -- with your
18 experience, 37 patents and 25 years in the field, can
19 you give the jury your general impression of Mr. Shaw's
20 patents?

21 A. Actually, it's 34 years in the field.

22 Q. Okay. Thank you.

23 A. Thank you for making me younger.

24 Mr. Shaw is the inventor of three particular
25 patents, what are they called the '077, the '224, and the

1 '733.

2 The '077 patent is essentially about a
3 contamination containment notion having to do with
4 safely tucking away the plunger, also aspects of venting
5 to prevent splatter, and that's generally the area of
6 concern or the bailiwick of the '077 patent.

7 The '733 patent concerns itself -- or the '077
8 is being asserted against the 3ml product, just against
9 the larger -- the larger product.

10 The '224 patent is -- concerns itself with how
11 it works, how does this invention work. And that's
12 being asserted, generally speaking, against both the 1ml
13 and the 3ml.

14 And, finally, the '733 patent really addresses
15 an assembly method and the syringe that's made by that
16 assembly method. And mostly, it has to do with
17 everything being loaded from behind, which is a terrific
18 way to assemble a product, especially automatically,
19 with automatic machinery.

20 And those claims are being asserted against
21 the 1ml product, Integra product.

22 Q. If you were a teacher on a class in medical
23 devices and patents, what would you give Mr. Shaw's
24 patents for a grade?

25 A. A plus.

1 Q. Why is that?

2 A. These are -- these are some of the most
3 impressive patents I've read, and I've read probably
4 thousands of patents.

5 And the reason is, the inventions disclosed in
6 these patents are so clever and so important for a
7 number of reasons.

8 One, he did a number of nonintuitive things.
9 In other words, he thought outside the box. Everyone's
10 heard that phrase outside the box. Well, that's what
11 this gentleman did.

12 The other thing is, he recognized that
13 syringes -- it may seem obvious as we sit here now, but
14 syringes are not just mechanical things. They're
15 hydraulic things. And one has to take into account what
16 happens when there's fluid inside, the hydraulic
17 pressures and issues like that.

18 And another thing he did was, against
19 conventional thinking, he created a press fit design for
20 holding in his retainer piece that most engineers -- and
21 I would count myself among them at the time, thinking,
22 oh, my gosh, that will never work and that, my goodness,
23 you're going to have to control tolerances so tightly,
24 and this is going to be tough to do.

25 And he sagely realized that these two pieces

1 of material -- remember, the cork stuck in the bottle --
2 that these two are going to come to an accommodation,
3 and they're going to fit -- they're all -- in the end,
4 they're all -- whether it's a slightly fatter cork or a
5 skinnier cork, in the end, they're going to fit together
6 and accommodate each other.

7 The barrel of a syringe is not so rigid as a
8 wine bottle.

9 And so those are just some of the highlights.
10 I mean, I was -- you know, I have 37 patents, and I
11 really appreciate great ideas, and I was -- I was very,
12 very struck by his invention.

13 Q. I think the Judge will instruct the jury at
14 the end of the case, when we talk about the issue of
15 whether Mr. Shaw's patents are valid, whether they
16 actually did something that wasn't known or obvious in
17 the art, that we have to look at that, not from today's
18 perspective, but rather from the perspective when
19 Mr. Shaw filed his patent application in 1995.

20 Now, were you involved in the art in 1995?
21 Were you a person that was working there?

22 A. Yes, I was.

23 Q. Okay. And in the 1990s -- let's take the
24 early 1990s. I think the evidence will show Mr. Shaw
25 began working on this in about 1989 and worked through

1 all the way to 1997 on the patents here.

2 In the late '80s, early '90s, just so we get
3 an idea of who was working on these problems, can you
4 tell the jury what kinds of people were -- were drawing
5 on pieces of paper and putting -- setting forth their
6 ideas of syringes, and in particular, retractable
7 syringes?

8 A. Sure. What's very interesting about this
9 whole issue about safety syringes and protecting
10 healthcare workers, it really galvanized a lot of
11 people.

12 Sadly, because of the HIV epidemic and AIDS,
13 the resulting infection and condition, because that was
14 just so horrible, and Hepatitis C -- actually, more
15 virulent, 10 times more virulent, is my recollection --
16 because of all of that was going on, a lot of people
17 rushed to solve the problem.

18 Okay. We got people getting stuck by needles
19 accidentally, nice nurses who were just doing their job,
20 and then they get stuck by a needle, and guess what?
21 They got AIDS. And where is the justice in that?

22 So a lot of people tried to solve this
23 problem. And for the most part, my understanding was,
24 for very altruistic reasons -- there are business
25 reasons, too, of course, but it's a win/win situation.

1 But if you look at the people -- and there
2 were hundreds. By the time Mr. Shaw filed this patent,
3 there were more than a thousand patents that had already
4 existed, had been issued, for safety-related devices in
5 connection with needles -- accidental needlesticks,
6 sharps injuries.

7 So a lot of people were busy. And the
8 people -- the type of people, it ranged from nurses,
9 doctors, folks who had never designed a medical device
10 in their lives, had seen something on TV and went, oh,
11 my God, I can figure that out, or I'd sure like to try.
12 There were folks -- you know, there were auto mechanics.
13 There were just all kinds of people mostly -- like in
14 the computer field, the next invention, you know, like
15 the iPhone, is not going to come from some -- some nice
16 person working at a gas station. They just don't know
17 about it.

18 And -- and so you're not -- you're not going
19 to see everybody jumping into that area.

20 But when it came to this needle safety,
21 everybody could relate to it. Everybody -- everybody
22 gets a flu shot, or everybody has had some kind of shot
23 or knows a diabetic in the family. My dad was a Type I
24 diabetic, so I've been around needles for a long, long
25 time.

1 But everybody jumped out and tried to solve
2 the problem. So it was a very broad range of people who
3 were trying, trying to design solutions.

4 Q. So do you have a -- sort of a summary? Have
5 you looked at documents or anything else to try to
6 further educate your opinion about the level of skill of
7 folks on a -- sort of an average level of skill of folks
8 working in this field?

9 A. Well, the average level of -- of skill was --
10 was -- was below what one would normally expect for a
11 traditional medical device.

12 Q. And that is because we had all these folks who
13 might not have engineering degrees but were trying
14 anyway?

15 A. That's exactly right.

16 Q. Okay. And we're going to talk today in detail
17 about Mr. Shaw's patent and its claims, because that's,
18 again, the reason we're here. But before we get there,
19 we heard in opening statement a little bit about a
20 couple of patents that came before Mr. Shaw's.

21 Mr. Beck put up about three or four, five, six
22 patents to show that Mr. Shaw was not the first one to
23 be issued a patent. And he showed specifically to this
24 jury -- in addition to Mr. Shaw's patent, he showed them
25 a patent from a Mr. McGary and a patent from a fellow

1 named Mr. Gillespie.

2 Were those the three -- were those -- was
3 Gillespie and -- I think Gillespie and McGary were both
4 issued patents before Mr. Shaw. Were those the first
5 three patents on retractable syringes?

6 A. Oh, goodness. Goodness, no. Those are just a
7 couple of trees in the forest. The forest goes -- goes
8 back hundreds of patents, hundreds of patents before
9 those.

10 Q. And did some of those earlier patents on the
11 general idea of retractable syringes, having a needle
12 that would come back in the barrel, did they -- did they
13 demonstrate the idea of having springs?

14 A. Oh, yeah, sure. Springs. No pun intended,
15 the first thing that springs to mind when you want to
16 retract something is, hey, I'll use a spring. And the
17 earliest ones, of course, used springs.

18 Q. And did some of them have -- they had
19 plungers, I take it?

20 A. Yes. A syringe -- a necessary part of a
21 syringe is the plunger that pushes the medicine and
22 medication into the person.

23 Q. And did some of them have vents and handles?

24 A. Not many but a couple.

25 Q. Okay. And so there were a lot of these

1 features -- would you say that some of the features,
2 individual features, that Mr. Shaw ended up placing in
3 his claims, the individual pieces were sort of in these
4 earlier patents?

5 A. Oh, sure. Remember, a patent claim is a list
6 of many different limitations and components. Many of
7 those individually and separately preexisted. Of
8 course, finger grips preexisted, and you'll see those in
9 the claims. But there are a number of things that
10 preexisted.

11 What is important is the novel combination of
12 these things. And that's -- that's the essence of -- at
13 least part of the essence of what Mr. Shaw did.

14 Q. Now, you looked at all those earlier designs,
15 and you've looked at -- pretty hard at what's available
16 in the marketplace and even the history a little bit.

17 A. Yes.

18 Q. So did you find any of those earlier
19 designs -- in all those hundreds of patents, did you
20 find any of those earlier designs on paper ever made it
21 into a plastic object that you could actually provide a
22 shot to somebody with and then have the needle safely
23 retract?

24 A. Not a single one. Not one was ever made, and
25 for very good reason. As they say, when you look at

1 these patents, you can see, oops, this person, although
2 well intentioned, didn't realize that you can't make
3 something like that, or that's going to take too many
4 parts, or it's going to be too difficult, or you're
5 going to have to glue a lot of things.

6 That would be the reasons.

7 Q. Now, the jurors have Mr. Shaw's patents in
8 their notebooks.

9 A. Yes.

10 Q. And on the front page of those patents,
11 there's a listing of other patents.

12 And can you tell the jury what that is, what
13 that listing of other patents on the front pages of
14 Mr. Shaw's patent is?

15 A. Sure. If you -- I assume they're in
16 chronological order?

17 Q. I believe so.

18 A. So --

19 (Juror giving her notebook to witness.)

20 THE WITNESS: Oh, I don't know that I'm
21 allowed to go there.

22 A. The earliest patent is the --

23 Q. (By Mr. Hardin) I think it's the '733.

24 A. It is the '733. Okay.

25 If you turn to the patent that begins -- no,

1 sorry -- that ends with the three numbers, '733 -- oh, I
2 have the same tab -- I'm sorry -- apparently. Thank
3 you, sir.

4 So it looks like it's Tab 3, and the number is
5 5. Up in the right-hand corner, beneath the bar code is
6 a 5,632,733.

7 Now, interestingly, what that means is that's
8 the 5 millionth, 632nd, 733rd patent issued since the
9 very first patent, since Thomas Jefferson was the
10 commissioner of patents.

11 Sorry. There's that one. That's his earliest
12 one. That issues in 1997. It's filed for in '95.

13 And on the front page, you see on the left,
14 before the -- above the picture, it says references
15 cited. This is after the certificate fancy page.
16 That's just -- that goes on the wall. That goes in a
17 frame.

18 You're looking at -- the actual page is this
19 page right here (indicating). This is what's called the
20 cover page. And the important part about the cover
21 page, at least for now, is this list of pieces of other
22 prior art. These are other patents.

23 So -- so -- and there are also some foreign
24 publications and documents.

25 So what happens is -- and -- and -- and the

1 inventor has the duty of candor, an ongoing duty of
2 candor -- and I know about that, because I've gotten 37
3 patents -- to tell the Patent Office, hey, these are --
4 these are some prior art things I know about that I
5 think you should look at, in all fairness.

6 And so you see that the Patent Office looked
7 at all of these pieces of prior art before issuing the
8 patent claims associated with this first patent.

9 Q. And, Mr. -- Mr. Sheehan, even with all those
10 patents, and when Mr. Shaw was filing his patent
11 application in 1995, I think the earliest one here, was
12 there still a need for this kind of invention where you
13 could actually give a shot to someone and have the
14 needle retract?

15 A. Absolutely.

16 Q. Now, did you see any documents in the
17 materials you looked at from the Becton Dickinson side
18 of the case from the documents --

19 THE COURT: Why don't we, before we go
20 into that, take our morning break.

21 MR. HARDIN: Oh, yes, Your Honor.

22 THE COURT: We'll be in recess 15 to 20
23 minutes.

24 COURT SECURITY OFFICER: All rise.

25 (Jury out.)

1 (Recess.)

2 COURT SECURITY OFFICER: All rise.

3 (Jury in.)

4 THE COURT: Please be seated.

5 You may continue your direct examination.

6 MR. HARDIN: Thank you, Your Honor.

7 Q. (By Mr. Hardin) Mr. Sheehan, just before the
8 break, we were -- I had asked you whether or not, even
9 with all of these patents -- prior patents relating to
10 safety syringes and even retractable syringes, if there
11 was still a need in the early or mid-'90s, and in
12 particular, if you had seen any document in -- from the
13 Becton Dickinson documents that confirm that.

14 A. Yes, sir, I did.

15 MR. HARDIN: Can I see --

16 A. Yes, sir, there was a need, and yes, sir, I
17 did see a document.

18 MR. HARDIN: Can I see Exhibit 22,
19 please.

20 Q. (By Mr. Hardin) Is this the document that
21 you're referring to, sir?

22 A. Yes, sir, it is. July -- yes -- 1992, yes.

23 Q. And what is -- what about this document
24 confirmed to you that there was still a need for a
25 retractable -- there was a recognized need for a

1 retractable syringe in the '90s?

2 A. Well, 1992, Becton Dickinson does this survey,
3 and the research verified the concept of the retractable
4 needle safety syringe indicating strong preference for
5 the product among current safety syringe users and
6 non-users.

7 And down here, you can see it's 52 to 39
8 preference for retractable, according to BD's own
9 studies in 1992.

10 Q. And had at least some of these prior patents
11 that we discussed already issued by that time?

12 A. Of course, yes.

13 Q. Does Becton Dickinson, to your
14 understanding -- let me ask the question this way: From
15 your review of the Becton Dickinson documents, did it
16 appear to you that Becton Dickinson engineers attempted
17 to solve this problem?

18 A. Yes. There's a document discussing about how
19 they did make an attempt and, in fact, tried their
20 hardest.

21 Q. Okay.

22 MR. HARDIN: Can I see Exhibit 55,
23 please.

24 A. This is the document --

25 THE WITNESS: It's a little hard to see.

1 There you go.

2 A. This is a document called Rethink
3 Retractable. And my understanding of the document is,
4 it's an internal document sent from BD headquarters out
5 to the sales and marketing folks about why you should --
6 sort of a talk against -- you should -- you should say
7 retractables aren't good.

8 And it says here that Becton Dickinson
9 engineers worked very hard trying to make this idea work
10 for us, but we could never get a retractable needle
11 syringe to perform to the standards, et cetera.

12 So by this date, they had already tried to do
13 it and -- and couldn't do it and were basically asking
14 their folks, go out there and tell the market, hey, it
15 can't be done. You know, buy our stuff, is essentially
16 the message?

17 Q. (By Mr. Hardin) Is there anything interesting
18 you find about the date of this document and the dates
19 of Mr. Shaw's patents that are here in this case?

20 A. Yeah. This is -- this is -- this is uncanny.
21 Eight days after this letter was written, Mr. Shaw filed
22 his first patent application and the string of
23 applications that led to these three patents showing
24 that the impossible was, in fact, possible.

25 Q. Now, we're going to get to these specific

1 claim terms and spend some time with them and compare
2 them to these accused devices, but what -- what do you
3 find in general that was different about Mr. Shaw's
4 inventions as compared to all those earlier designs for
5 a retracting syringe?

6 A. Well, Mr. Shaw's VanishPoint syringe has the
7 distinction of being the only one that was ever made
8 that ever worked that ever saved a life.

9 Q. Now, how did Mr. Shaw's approach -- and so all
10 these folks were trying to solve essentially the same
11 problem. How did Mr. Shaw's approach differ from all
12 those other folks' approach, in your opinion?

13 A. Well, as I mentioned earlier, Mr. Shaw
14 recognized that this was not just a mechanical problem
15 to try to solve, it was a hydraulic problem. It was
16 also a materials problem in the sense of how materials
17 behave.

18 And it was also a recognition of the
19 accumulation of forces that are required to activate a
20 syringe, to deliver the medication and then activate the
21 safety syringe. That force can never be so high that
22 the smallest nurse can't activate it. If you can't make
23 it safe, then it's -- then it's no good.

24 But finding that is the notion that inside of
25 these syringes, believe it or not, is something on the

1 order of a hundred psi of pressure or more than three
2 times your tire pressures.

3 And interestingly, the smaller the syringe,
4 the higher the pressure, because the area's smaller.
5 It's a little counterintuitive, but there's an
6 incredible amount of pressure inside of these syringes.

7 And so you do not want your retraction
8 mechanism, your safety mechanism, to be inadvertently or
9 too early activated by that high pressure. And that's
10 another thing that Mr. Shaw addressed in his patents.

11 Q. Could you -- do you have -- just so the jurors
12 understand, you say a hundred psi. I think I said in
13 opening three or four times a garden hose pressure.

14 A. Sure.

15 Q. Can you demonstrate for the jury -- you're
16 talking about the pressure that's developed when the
17 thumb is pressing against the medicine to deliver it to
18 the patient, correct?

19 A. That is correct.

20 Q. Okay.

21 A. Well, that's the -- the force -- sorry. I'm
22 filling up.

23 The force generated by the nurse is between 6
24 and 8 pounds, something like that, comfortably. And
25 that also has to be generally the range of the

1 activation force to activate it.

2 Because if it takes more than that to activate
3 it, then you can't activate the safety syringe, the
4 safety aspect of it.

5 MR. HARDIN: With -- with the Court's
6 permission, can the witness just demonstrate how far
7 water goes in the courtroom?

8 THE COURT: Yes. This is Judge Ward's
9 courtroom. We'll go ahead.

10 THE WITNESS: Now, with my apologies to
11 Ms. --

12 THE COURT: Why don't you go maybe --
13 maybe this direction.

14 THE WITNESS: We're still friends, okay?
15 (Demonstrating.) There's a lot of pressure. I shot it
16 over there, and it, you know, would have kept on. I
17 would have had...

18 THE COURT: Mr. Potts, maybe we should
19 dry it, so we don't have Judge Ward --

20 THE WITNESS: Sorry.

21 THE COURT: -- too angry at us.

22 MR. HARDIN: We apologize to Judge Ward
23 in advance, Your Honor.

24 Q. (By Mr. Hardin) Now, you said Mr. Shaw
25 appreciated this large pressure of force that was part

1 of the problem of creating one of these devices.

2 What were -- obviously, they're may be more
3 than one solution, but what was one of the solutions
4 that Mr. Shaw built into his designs?

5 A. Well, one of -- one of the things he built
6 into his design -- one of his designs was that there was
7 a step-down. There was a step-down from a barrel
8 diameter through a little transition zone and then into
9 the nose so that the area -- the smaller you make the
10 area, the less the force is going to be given a certain
11 pressure.

12 And so it was smart to bring that down in
13 size, number one.

14 Q. Okay. And does -- we're going to talk a lot
15 about something called the retraction mechanism, the
16 actual mechanics that pull the needle back up.

17 A. Yes, sir.

18 Q. Did Mr. Shaw recognize anything about how
19 pressures might interact and what shouldn't be happening
20 with the retraction mechanism?

21 A. Could I have a little more definition?

22 Q. Yes. The retraction mechanism in this case is
23 in the front part of the device.

24 A. Correct. It's in the nose.

25 Q. Right. And does it have to act -- first of

1 all, before we get to the retraction mechanism, do you
2 have to have any kind of a seal in the nose of the
3 device, in the front part of the device?

4 A. Oh, no. Oh, of course. Of course.
5 Holding the spring down -- because this spring is the
6 thing that's going to fire the needle-holder back up
7 safely into the plunger and inside the body -- the
8 barrel of the -- of the syringe.

9 So, obviously, to begin with, you have to have
10 a seal up front. And the spring, of course, you don't
11 want to be in the fluid path, so that's on the other
12 side. That's on the dry side, if you will.

13 And then there's a -- a retainer, a
14 needle-holder. And all that has to be sealed. Fluid
15 can't go past that, especially when you're generating
16 the high pressures that I just -- when I cleaned the
17 wall.

18 Q. So did Mr. Shaw's invention, does it involve
19 any way -- in any way the placement or how that seal is
20 combined in the syringe?

21 A. Yes. Some of his claims address the fact that
22 they're all installed from behind.

23 So much of the prior art has designs where you
24 have to put something on in the front; you have to put
25 something on in the back. And I'm not just talking

1 about gluing a needle; I'm talking about serious
2 assembly.

3 And one of the beauty parts -- it's in the --
4 it's in the '224 patent asserted against the 1ml
5 Integra -- is that essentially everything is loaded in
6 from behind.

7 And this lends itself to automatic assembly.
8 If you've ever been around any kind of automatic
9 assembly or seen it on TV -- there are a lot of shows
10 that show it now. I love it. It's a joy to behold.
11 Excuse me. And that's another aspect.

12 Q. And wouldn't just putting things in from
13 behind and kind of stuffing them upfront, wouldn't that
14 be something that would ordinarily be considered by
15 someone?

16 A. Sure. I mean -- I mean, that's, you know, one
17 of the approaches, but -- but what you have to do is be
18 able to create a seal.

19 And what Mr. Shaw was able to recognize --
20 well, wouldn't be able to; he did -- is that he could
21 create a seal using friction.

22 And in this -- I mentioned earlier, this is
23 the kind of thing that actually when I read it, I said,
24 oh, my gosh, that will work? I don't think so. And
25 yeah, it does.

1 And so he's able to load everything from the
2 back without having to go -- without having to push past
3 hooks or other kinds of complicated little mechanisms.
4 The prior art -- and that means all of those older
5 patents -- is riddled with such, oh, complicated Rube
6 Goldberg kind of mechanisms.

7 Q. Now, in addition to dealing with those
8 hydraulic forces, you said -- you told the jury just a
9 few minutes ago that when you get down to the end of the
10 injection, the device has to be such that even the
11 smallest nurse can use it, because, otherwise, if you
12 put it in the marketplace, you have to put like for use
13 by persons over 150 pounds or something.

14 A. Sure.

15 Q. So was that another problem that Mr. Shaw
16 addressed?

17 A. Yes. Yes, absolutely.

18 In order to maintain a low overall force,
19 remember, you have to do essentially three things with
20 this safety syringe.

21 You have to deliver the medication. Once
22 that's done, you have to release the seal. You have to
23 release the needle to fly back. And then you have to
24 make the container resistant to -- to -- to tampering or
25 inadvertent sharps risks.

1 And historically, in the prior art, that
2 consisted of three different force amounts, like boom,
3 boom, boom, or -- and they would overlap each other. So
4 in many ways, they were additive.

5 And what Mr. Shaw realized is that he could
6 combine the first two into one piece, one piece or one
7 assembly, and get the seal and release mechanism all at
8 once, one force.

9 Q. So -- I want to stop you there --

10 A. Sure.

11 Q. -- because I want to make sure that we're
12 getting this point correct.

13 So if you have a syringe and you need to seal
14 it against this huge pressure inside, then that has to
15 be -- that has -- that has to withstand a force,
16 correct?

17 A. Correct. It has to be sturdy enough to
18 withstand 100 to 120 psi.

19 Q. So when the nurse's thumb comes down and she's
20 got all the medicine in the body, then she's got to be
21 able to push through that somehow; something has to
22 happen to let the needle fly back up; is that correct?

23 A. That's correct.

24 Q. And is that what you were terming release?

25 A. Yes. I'm sorry. That's release. When you

1 release the retraction mechanism so it can fire back.

2 Q. And so Mr. Shaw's particular retraction
3 mechanism that was -- that he developed in these
4 patents, what did it do with those two forces?

5 A. It combined them. That was the deal. At
6 the -- at the same time that you break the seal, you
7 also release the mechanism.

8 Q. Now, is there any other forces that's -- that
9 are dealt with in these patents beyond those forces,
10 with respect to using the needle in a way that's
11 practical for even small hands?

12 A. Yes. And this is -- this is really subtle,
13 and I love this. When you -- I can't -- this one has
14 already been activated, so I can't get it out. So I'm
15 going to have to open up another one. And this is a
16 VanishPoint syringe, but it could be demonstrated on
17 others.

18 But, see, this is the plunger, and, you know,
19 I would be pushing on this, and eventually, this gets
20 pushed -- and I'm going to activate this -- and this
21 plunger will lodge itself, will go down inside this
22 collar like that (demonstrating).

23 And you can't get at it. You can't -- I mean,
24 if you had a pen knife, sure, you could dig it out and
25 everything like that, but that's not the point. The

1 point is that it's inaccessible for grasping by some
2 nurse who thinks, gosh, maybe I can use -- this is a new
3 syringe. I'll use this.

4 Now, this -- this prevents her, deters her
5 from doing that. And the great thing is, no extra force
6 was needed to make it go down below that level. Sounds
7 simple, but no one had thought of it before in this
8 combination.

9 Normally, all of the -- or the other prior art
10 devices had a locking mechanism. For instance, there
11 was a patent mentioned, the McGary patent, that had a
12 locking mechanism where you would go down inside, and it
13 was supposed to push past this whole ring and try to
14 force it in there. Well, that would give an incredible
15 amount of force to try to overcome.

16 So in summary, it -- Mr. Shaw combined the
17 first two forces into one so they weren't additive and
18 eliminated the third force, the so-called locking force,
19 because you don't have to lock it. You can't get at it.
20 You know, it's like the kids. You don't have to lock
21 the cookie jar; you just have to put it up on the shelf.
22 You don't have to lock it; just put it on the shelf, and
23 you can't get at it.

24 And that's -- I know to some that seems, gee,
25 that's obvious, but it hadn't been done before in a

1 retractable syringe. And it was very clever to lose
2 that force element in the locking aspect.

3 Q. So instead of having to go past this lock or
4 mechanical lock, you simply -- it simply tucks the --
5 the claim has -- is the word tuck in these claims
6 anywhere?

7 A. No. This is a -- my shorthand for what
8 generally happens. You bring the head -- the thumb
9 press on the plunger down to a place where you can't get
10 it.

11 Q. Okay. Now, we heard a little in the opening
12 about something called venting, some venting?

13 A. Yes, sir.

14 Q. Did Mr. Shaw use vents and venting principles
15 in coming up with his patents?

16 A. Yes, he did, and it's described in his
17 patents.

18 Q. Okay. And what did Mr. Shaw -- what does
19 Mr. Shaw describe as the reason for putting vents or
20 venting in his products?

21 A. The purpose of putting vents in his product is
22 to prevent splatter or fluid coming out of the front end
23 of the syringe during retraction.

24 Now, of course, if one uses the RTI syringe
25 properly, they're retracting -- retracting it while it's

1 in the body. And so the risks of splatter are
2 absolutely miniscule.

3 Nonetheless, there are -- the vents minimize
4 anything that might possibly come out of the front as a
5 consequence of any pressure that's built up as it -- as
6 the needle slides back.

7 Q. Now, we talked earlier about some of the
8 features of Mr. Shaw's inventions, and are those
9 features -- by the way, are we going to see them in just
10 a little while described perhaps in more precise
11 language in the claims of these patents?

12 A. That is correct.

13 Q. Okay. And do the Becton Dickinson devices
14 use -- there are different claims covering different
15 devices, but do they -- do one or the other devices use
16 those features?

17 A. Yes, sir.

18 Q. Okay. Now, we also talked about all these
19 earlier patents that were out there.

20 A. Yes, sir.

21 Q. And do any of those earlier patents talk about
22 venting, or as you say, pressing something down into a
23 collar?

24 A. Yes. The notion of venting and the notion of
25 tucking predate Mr. Shaw's invention. They appear in a

1 couple of patents but never in association with the
2 other limitations in the claim. So his combination is
3 novel.

4 Q. Okay. Did the Patent Examiner know that there
5 was a patent out there that had a hole or a vent in the
6 plunger handle in a retractable syringe while he was
7 looking at Mr. Shaw's patents?

8 A. Sure. He had the Murray patent to look at.

9 Q. Okay.

10 MR. HARDIN: Can we see that, please,
11 Exhibit 37.

12 Q. (By Mr. Hardin) Is this that patent?

13 A. That is the Murray patent, yes.

14 Q. Okay. And this was one of the things the
15 Examiner looked at before he issued Mr. Shaw's patents?

16 A. That's correct.

17 Q. Okay.

18 MR. HARDIN: Can we look at -- do we have
19 a blowup of it? There we go.

20 Q. (By Mr. Hardin) And can you tell the jury
21 where the vents are in this?

22 A. Up here -- oops, that's the blinky button. Up
23 here you see these vent holes right there (indicating),
24 and those vent the interior chamber of the plunger of
25 this particular design.

1 Q. Now, what did Mr. Murray teach about those
2 vents?

3 A. Mr. Murray teached (sic) that those holes were
4 there as a way of reducing the pressure, not at the
5 front end of the syringe, but inside and behind this
6 little piston thing that came flying up, along with this
7 part which grabbed this needle and all -- and everybody
8 headed north.

9 So the purpose of these vent holes was to vent
10 this area up here as this flew up (indicating).

11 Q. Did anybody, to your knowledge, in any of
12 these prior patents ever discover what Mr. Shaw
13 discovered; that is, that you could use vents in the
14 back to stop the fluid from coming out the front?

15 A. No. He's the first, and it's described in
16 this patent --

17 Q. Okay.

18 A. -- patents.

19 Q. What about the use of this collar? You said
20 that he used this collar to reduce the forces in a
21 retractable syringe.

22 Was there -- was there any use -- were there
23 any prior patents that showed use of this collar first
24 at all?

25 A. Yes. One or two disclosing -- oh, collars?

1 Q. Collars.

2 A. Collars, sure. A few of them had collars.

3 Q. Right. Any of those in a retractable syringe?

4 A. No.

5 Q. Okay.

6 MR. HARDIN: Can I see Exhibit 433.

7 Q. (By Mr. Hardin) Is this one of those prior
8 patent documents?

9 A. Yes, it is.

10 Q. And does it have a collar where the plunger
11 tucks in the back?

12 A. Yes. Here's a collar, and here's a plunger.
13 And this has a bonus cap on top. And that when this
14 is -- when it's delivered, the fluid is delivered, this
15 tucks underneath there (indicating) ---

16 Q. Is this --

17 A. -- below that.

18 Q. Is this use of that little collar, is that the
19 same use that Mr. Shaw put it to?

20 A. Well, to the extent that it makes it
21 inaccessible, generally speaking, yes. But, of course,
22 this is not a retractable syringe and nor does it have
23 venting.

24 Q. And why is that -- why is that important with
25 respect to locking and forces?

1 A. Remember that whole point about tucking was
2 about reducing the locking -- removing the locking
3 force, just taking that away. And that's -- that's the
4 essence of -- and that in combination with the other
5 limitations in those claims is why his patent is -- is
6 novel.

7 Q. And was this -- was this document considered
8 by the Patent Office before they gave Mr. Shaw his
9 claims?

10 A. Yes. That patent was being considered by the
11 Patent Office at the time they were reviewing Mr. Shaw's
12 application.

13 Q. Okay. Let's come down -- back to one issue
14 that we've -- came up in opening, came up several times,
15 and will come up throughout this case, which is the use
16 of cutters, the use of cutters or cutting in a
17 retractable syringe.

18 Is it your understanding that Mr. Shaw's
19 claims, as found by this Court, can cover -- can have
20 within their boundaries a retractable syringe that
21 employs a cutter?

22 A. Absolutely.

23 Q. Now, does he also have in that same patent a
24 design that doesn't require a cutter?

25 A. Yes, sir.

1 Q. And why is that in these patents that you --
2 that they -- does he have separate designs?

3 A. Yes. Within the patent, there will often be
4 more than one -- what's called an embodiment. And in
5 Mr. Shaw's patents, there are three embodiments.

6 And one of them uses two separate pieces, a
7 retainer and a needle-holder.

8 Another -- another one uses no retainer.
9 That -- that embodiment is not in -- in discussion
10 today.

11 And then the third embodiment is using a
12 bridging portion.

13 So there are two primary embodiments that
14 we're looking at today.

15 Oh, and here you go.

16 Q. So on the left, we have a graphic, and why
17 don't you walk the jury through the graphic, again, just
18 to describe the two different -- embodiments, is that a
19 big word for two different designs?

20 A. Correct.

21 Q. Okay.

22 A. Yes. This is --

23 Q. Would you walk the jury through the two
24 different designs that Mr. Shaw disclosed in his patent?

25 A. Certainly.

1 If you look here, you'll see the barrel and a
2 little transition zone and then a nose area here
3 (indicating). And you see that on both of them. That's
4 common.

5 And here, the plunger is -- they're
6 essentially the same plunger. The spring is the same.
7 The actual tiny little needle that's been glued into the
8 needle-holder, this long piece here (indicating), that's
9 all the same.

10 But what's different here is, in blue here
11 (indicating), you see a separate outside retainer
12 member. This is a non-retractable part. This part does
13 not retract.

14 Inside of it --

15 Q. Meaning it just doesn't come up in the barrel?
16 Is that what you're talking --

17 A. Correct. It doesn't go that way. It goes
18 this way or perhaps not move.

19 But when you look in here -- and I hope it's
20 clear -- here is a cross-section of this internal
21 needle-holder part, and you can see this is where the
22 fluid flows down this little part here (indicating).
23 And now between this part (indicating), the yellow
24 needle-holder part, and the blue retainer part, there is
25 also a friction fit.

1 Now we've got two friction fits. You got a
2 friction fit between the nose and the retainer and
3 another one between the retainer and the needle holder.
4 That's one design.

5 In the other design --

6 Q. Excuse me.

7 A. Okay.

8 Q. But is this the design that we heard -- we saw
9 Ms. Duesman this morning using what she called a
10 VanishPoint syringe.

11 A. Yes.

12 Q. Is that the design that's in that syringe?

13 A. Correct.

14 Q. Okay. Now -- but in the patent, there's this
15 other design, correct?

16 A. That's right. That's right. This -- this is
17 the design used by the VanishPoint product, but that's
18 not what we're comparing it to.

19 This is the other embodiment where it uses
20 what's called a bridging portion. And the reason all of
21 this is yellow is because all of this is the same
22 material.

23 Here's that elongated needle-holder, just like
24 before. Here's the fluid path coming down here. And
25 now the -- and this head right here, that's the

1 needle-holder. The skinny part going around the outside
2 is the retainer, once again, the non-retractable part.
3 And then this is a bridging portion, and it goes over
4 this gap area (indicating).

5 You know, a bridge -- in order for there to be
6 a bridge, it has to bridge over something, so that's the
7 gap that it bridges over.

8 And this is the second embodiment. And, yeah,
9 there's a little something right there.

10 Q. Okay.

11 A. Third embodiment but the second of these two.

12 Q. Now, in both of these designs, what's
13 holding -- what's holding the needle-holder from
14 springing back up into the syringe body?

15 A. What's holding it from springing back up is
16 friction or clamping.

17 Q. Between that retainer member and the barrel?

18 A. Well, in this one, between the retainer member
19 and the nose portion of the body; in this one, it's
20 friction here and friction there (indicating).

21 Q. So we've got two friction and one friction,
22 essentially.

23 A. Yes.

24 Q. Okay.

25 A. On the left, we have two friction; on the

1 right, we have one friction.

2 Q. Okay. Now, is there anything in the claims --
3 we're going to talk -- we're going to start talking
4 about the claims and ask the jury to follow with us as
5 we describe how these Becton Dickinson devices fall
6 within the scope of those claims inside those
7 boundaries.

8 A. Yes, sir.

9 Q. And to do that, they have to compare those
10 devices, as you have, to the words of those claims,
11 correct?

12 A. That's correct.

13 Q. Okay. Now, is there anything in the words of
14 those claims that says you can't release the friction
15 using a cutter?

16 A. No, absolutely not.

17 Q. Okay. And do you see some specific part of
18 the claim that the Court has instructed that you think
19 leads you to that conclusion?

20 A. Yes. If we could look at the Court's claim
21 construction for retainer member or continuous retainer
22 member.

23 Q. Let's see. So -- so this is a -- that's kind
24 of fuzzy, but the jurors -- and you and I can look at
25 Tab 4. This is that page that Mr. Carroll referred to

1 this morning as sort of the -- what the legal judge in
2 this case has given us.

3 And this is the Court's orders or judgment as
4 to what some of the words in these claims we're going to
5 look at mean; am I correct?

6 A. That's absolutely correct.

7 Q. Okay. And which of these -- we have a list of
8 terms on the left. It's got -- and these terms come
9 from where, the list of terms on the left?

10 A. The list of terms on the left come from the
11 claims. What happens is, either the sides have a --
12 meet and decide very carefully what each word actually
13 means, and with the help of the Court, who has the final
14 word, decides exactly what -- what a word or a phrase
15 means for the purposes of -- of this matter.

16 Q. So -- so what the Court has decided these
17 words mean are in that second column over on the right.

18 A. That's correct.

19 Q. Okay.

20 A. That's known as the Court's construction or
21 interpretation of the words on the left.

22 Q. Now, is there a particular word or phrase here
23 on the left that you think tells you that a syringe
24 design that has a cutter could be still included in --
25 in fact, is included, in the claims of Mr. Shaw's

1 invention?

2 A. Certainly. If you look at the eighth one
3 down, it's the one that has the -- kind of the larger
4 area called retainer member. Yeah, it's zoomed up on
5 the screen, but it's a little fuzzy. But that will tell
6 you which one it is.

7 And the language there is -- this is the
8 Court's construction of the term retainer member: A
9 non-retractable part of the retraction mechanism that
10 uses some clamping or frictional force to keep the
11 needle in the projecting position until that clamping or
12 frictional force is released.

13 Q. Now, does it say anything there about what has
14 to be used to release that frictional force?

15 A. No, absolutely not. There's no limitation on
16 what does that.

17 Q. And so as far as the wording in this claim,
18 does it matter whether it's a cutter, whether it's cut
19 off, broken off, pushed off?

20 A. No. It can be ruptured, fractured, cut,
21 anything.

22 Q. Okay. Now, also in this claim term, does it
23 say that what's -- what's holding this down there has to
24 be exclusively friction?

25 A. No, it does not.

1 Q. What does it say on there?

2 A. Within -- within the same limitation?

3 Q. Yes.

4 A. Okay. Focus on the word some. It says a
5 non-retractable part of the retraction mechanism that
6 uses some clamping or frictional force, some clamping or
7 frictional force. Not entirely, not 80 percent, not
8 whatever, but some.

9 Q. Now, is there some -- anything else in the
10 claims, other than a forward movement of the plunger,
11 that's required by the claims to release this
12 needle-holder?

13 A. No. That's all that's required. The forward
14 movement of the plunger releases the needle-holder. And
15 that's where the needle is, and that's what you need to
16 retract.

17 Q. Does Mr. Shaw teach in his patents ways to
18 release frictional holding?

19 A. Yes, he does.

20 Q. And how does he teach that can be done?

21 A. He teaches -- in one section of the patent, he
22 uses the phrase to rupture, fracture, or otherwise
23 separate.

24 Q. Okay.

25 MR. HARDIN: Can we see Exhibit 5.

1 Q. (By Mr. Hardin) This is the patent-in-suit,
2 correct? This is the '733 patent-in-suit.

3 And in the --

4 A. Which Exhibit 5? Which book?

5 Q. I'm sorry.

6 A. I don't think it's 5.

7 Q. It's 5 in the court record, but,
8 unfortunately, we didn't put the jury notebooks together
9 until later. It's Exhibit 1 in the jurors' notebooks.
10 Actually, I think it's Exhibit 3, isn't it?

11 A. '733 is Exhibit 1 in the jurors' notebooks, I
12 believe.

13 Q. Right. Let's look at -- let's look at --

14 MR. HARDIN: Can we have Column 2,
15 Lines...

16 There we go. Okay.

17 Q. (By Mr. Hardin) This is from Column 9, I
18 believe, in the '733 patent.

19 Now, how does that statement in the patent
20 relate to this issue of what's releasing?

21 A. Okay. Just -- just to follow along, it is in
22 Column 9 of the '733 patent, and you have to go down to
23 about Line 51.

24 Within the patents, there are these little
25 numbers down the middle, 5, 10, 15, 20, 25, 30, and it

1 kind of shows you approximately where the lines are.

2 They don't line up so well.

3 But if you're looking at the '733 patent,
4 Column 9, find the numbers in the middle, go down to
5 sort of the 50-ish area, go to your left, and you see
6 that 22a that's not highlighted up on the screen?

7 That's the end of the last sentence. That's
8 not like a number of this area here.

9 Yeah, you can see that's where it comes from.

10 Thank you.

11 And now if you zoom back, we'll just take a
12 look at the language.

13 And it says any tack weld connecting the
14 separable parts at the bridging portion is ruptured,
15 fractured, or otherwise separated so as to separate
16 Retainer Ring 66 from Inner -- Inner Head 72a, thus
17 releasing Needle-holder 22a from further restraint.

18 So, essentially, that describes -- I couldn't
19 describe -- have said it better. That describes what
20 I -- what I just described myself.

21 Q. Okay. And is cutting one way of separating?

22 A. Oh, sure.

23 Q. Now, we saw in opening statement another
24 statement from this same patent.

25 MR. HARDIN: If we can, if we can look

1 back at Column 2 of this same patent.

2 Q. (By Mr. Hardin) In Column 2 of the '733
3 patent, there's some statements that were shown to the
4 jury, I think, in -- either read to them or shown to
5 them in opening where Mr. Shaw was describing what went
6 before.

7 Do you remember some of those statements, sir?

8 A. I do.

9 Q. Okay.

10 MR. HARDIN: Do we have a blowup of those
11 statements?

12 Q. (By Mr. Hardin) Okay. And in this part of the
13 patent, Mr. Shaw is trying to express what's going on
14 before.

15 A. Yes, sir.

16 Q. Okay. And I think in particular, if we look
17 down about -- let's just start where the paragraph
18 begins, okay, where it says the prior art.

19 You see that, sir?

20 A. Yes, sir, right here.

21 Q. It says, the prior art has not recognized
22 retraction mechanisms -- that's this thing we're talking
23 about, correct?

24 A. Right. The mechanism consists of the
25 retainer, the needle-holder, the spring, et cetera.

1 That -- that is the mechanism that fires the
2 needle-holder back.

3 Q. Okay. The prior art has not recognized
4 retraction mechanisms with separable parts -- that's
5 these parts that separate, correct?

6 A. Yes.

7 Q. -- that relies entirely on clamping or
8 friction at a smooth-walled reduced diameter transition
9 zone in the barrel with mating lands, which are slidably
10 or separably released, in response to relatively low
11 thumb pressure while having a resistance to premature
12 retraction and high-pressure blowout resulting from high
13 pressure produced in the fluid chamber during an
14 injection.

15 Is that this concept of having to have low
16 thumb pressure for the nurse but guarding against this
17 high internal pressure?

18 A. That's exactly right. It's a great
19 description of what I tried to describe earlier.

20 Q. Okay. It continues, the prior art has not
21 recognized that such a structure can be molded as a
22 one-piece outer body over a core that can be pulled out
23 from behind allowing the retraction mechanism to be
24 easily pushed into place and steered by the narrow nose
25 portion.

1 Is that this concept we described generally
2 about the advantage of being able to mold it and then
3 combine -- produce it or manufacture it?

4 A. Yes. To be able to mold the entire syringe
5 body out of one piece -- and here, obviously, the core
6 pin is what he's referring to -- coming up behind --
7 where it says the word core, we molding folks call it a
8 core pin; a core pin that can be pulled out -- and that
9 allows the retraction mechanism to be easily pushed into
10 place from behind and steered by the narrow nose
11 portion.

12 That's what I was trying to describe earlier.
13 It's in the patent.

14 Q. Okay. And, finally, it says neither --
15 neither does the prior art, in such a combination,
16 realize the desirable non-cumulation of forces resisting
17 retraction in order to minimize the thumb force required
18 having a most simple tamperproof feature and the fewest
19 number of easily made parts.

20 Does that have to do with this tucking in the
21 back, as you called it?

22 A. Absolutely. That's another great portion of
23 the patent to read.

24 Q. Okay. Now, there was some characterization --
25 we talked about friction and clamping, and that is an

1 important part of Mr. Shaw's invention, correct?

2 A. That is true.

3 Q. But is his invention just limited to features
4 that deal with friction and clamping?

5 A. Oh, goodness, no.

6 Q. And are these -- this venting concept and this
7 reducing of locking pressures, are those directly
8 related to friction?

9 A. No. Those are in addition to.

10 Q. Okay.

11 A. There are a number of features and aspects in
12 his inventions, which you'll see when we eventually do
13 get to the claims limitation by limitation, that -- that
14 in combination are novel --

15 Q. Okay.

16 A. -- new.

17 Q. Now, we're just about to get to the part where
18 we're going to talk about the infringing devices and
19 look -- and look at them and compare the language of the
20 claims to each of those products.

21 A. Yes, sir.

22 Q. But before we get there, there was much
23 discussion again in opening statement about one
24 particular patent. It's called the McGary patent.

25 A. I recall.

1 Q. Okay. And there was a suggestion that the
2 McGary patent shows basically what Mr. Shaw's invention
3 shows, same thing.

4 A. I guess they made that suggestion.

5 Q. Okay.

6 A. It's not true, but...

7 Q. All right. First of all, the McGary patent
8 was one of the patents the Examiner had in front of him
9 at the Patent Office before he gave Mr. Shaw his patent?

10 A. That is correct. They were well aware of it.

11 Q. And we're going to go through each of claims
12 together, but before we do that, did you take a look at
13 the McGary patent and identify the distinctions that are
14 in the actual wording of Mr. Shaw's claims that you
15 don't find in the McGary patent?

16 A. Yes, I did. I made such a comparison.

17 Q. Okay.

18 MR. HARDIN: Can we see that?

19 Q. (By Mr. Hardin) Okay. And are these features
20 words in the claims of Mr. Shaw's patent that we're
21 going to describe -- these are like pieces of the
22 boundary; is that correct?

23 I've got -- we haven't got a box here. We've
24 taken -- we've taken a leg from this claim and a leg
25 from that claim, and in a moment, we're going to look at

1 them all together.

2 But each of these statements, 1 through 10, do
3 they come from these boundaries and descriptions in the
4 claim?

5 A. Correct. These are limitations -- these are
6 actual words from the actual claims. It will be hard --
7 I'm glad nobody's looking -- to find them, because they
8 come from different claims, but it will be explained
9 shortly.

10 And these are in addition to the use of
11 friction or clamping, which is something that Mr. Shaw
12 invented. These appear in the other asserted claims.
13 And what I did was, I looked for these -- these appear
14 in Mr. Shaw's inventions, and I looked to this older
15 McGary patent, which -- to see if -- if they came from
16 there, if they even appear in there. And I will --

17 Q. Okay.

18 A. We can go through it, if you like.

19 Q. Yeah. I'd like to -- I'd like you to go
20 through them just as quickly as we can.

21 Number one, the plunger seal element, being
22 restrained from sliding longitudinally along the outer
23 wall at the plunger, that's one of the things that
24 Mr. -- is in Mr. Shaw's patent that is not in
25 Mr. McGary's patent?

1 A. That is correct. It refers to this little
2 black part here (indicating) not being able to move on
3 the plunger.

4 In McGary, it does.

5 Q. Okay.

6 MS. PIROZZOLO: Your Honor, may we
7 approach?

8 THE COURT: Yes.

9 (Bench conference.)

10 MS. PIROZZOLO: I corresponded over the
11 weekend about whether RTI was going to put on its
12 invalidity case in its case-in-chief, and you sent back
13 an e-mail saying --

14 MR. HARDIN: I said -- I said we were
15 going to generally talk about invalidity here and would
16 save our actual rebuttal validity case for --

17 MS. PIROZZOLO: We don't think you can do
18 it twice and now you are putting on specific claim
19 elements and putting on an invalidity case.

20 MR. HARDIN: I'm not putting on an
21 invalidity case. I'm -- there was a big thing in the
22 opening about, essentially, we're practicing
23 Mr. McGary's patent.

24 What I'm showing is that his patent has
25 elements that are not in the McGary patent, not the type

1 in this case.

2 THE COURT: Well, what was your agreement
3 about putting on your invalidity?

4 MR. HARDIN: I told them that I would be
5 talking about invalidity, but I would be change -- I
6 would be -- I told them, I said I'm going to mention
7 invalidity.

8 MS. PIROZZOLO: Mention?

9 THE COURT: Well --

10 MR. HARDIN: But I'm going to save --
11 obviously, I have to save my defense for after I see
12 their case.

13 MS. PIROZZOLO: This is much more than
14 mentioning, Your Honor.

15 MR. HARDIN: Your Honor, in the opening,
16 you heard all --

17 THE COURT: I understand all about the
18 opening.

19 Well, it seems like you're going way past
20 the -- what seemed to be the agreement of the parties.
21 So I would suggest you save this for your defense.

22 MR. HARDIN: Okay. That's fine.

23 MS. PIROZZOLO: Thank you, Your Honor.

24 (Bench conference concluded.)

25 Q. (By Mr. Hardin) So as to not get real

1 confusing about -- because these are things from
2 different claims. I think I said a minute ago --

3 A. Yeah.

4 Q. -- that there are several things. We are
5 going to come back to this after we've looked at the
6 claims themselves, okay?

7 A. Okay. Sure.

8 Q. So let's go to the claims themselves. And
9 your opinion -- here's your actual opinion of what we're
10 asking this jury to find, which is -- their job at the
11 end of this case is going to be to look at the BD
12 Integra syringes and see if they fall within the scope
13 of claims that we're asserting in this patent -- from
14 these patents; is that correct?

15 A. Yes, sir.

16 Q. Okay. So let's go patent by patent, if we
17 can.

18 A. Yes, sir.

19 Q. Let's start with the '077 patent. That's the
20 one that is at Tab 2 of the jury notebook.

21 And what claims are we asserting? What
22 numbered paragraphs at the end of this patent are we
23 asserting are infringed by Becton Dickinson -- Becton
24 Dickinson's products?

25 A. RTI is asserting that Claims 10 and 25 are

1 infringed by BD's Integra 3mL syringe.

2 Q. Okay.

3 A. And that claim, Claim 10, can be found in the
4 patent at Column 19.

5 You notice there are two columns on each page,
6 and if you go to Column 19 about halfway down, you will
7 see the No. 10.

8 And the words there in the patent have been
9 reproduced up on the slide. You don't have to follow in
10 the patent, because they're up on the slide.

11 Q. Okay. And is there another claim from this
12 patent?

13 We'll come back to this claim. But just as an
14 overview, is there another claim from the patent that's
15 being asserted against one of these --

16 A. Yes. Claim 25, which appears on the same page
17 over in Column 20.

18 Q. Okay. So this patent -- in short, is this
19 patent -- this patent is being asserted against one of
20 their products; is that correct?

21 A. Yes. It's only being asserted against the 3ml
22 syringe, not the 1ml but the 3ml, the larger one.

23 Q. Now, can you give the jury just an overview --
24 we're going to go through Claims 10 and Claims 25 with
25 precision.

1 But the Court -- what the law requires us to
2 do is to demonstrate to the jurors that for each line of
3 text up there, each description of a structure, that
4 Becton Dickinson reflects that structure.

5 Is that your understanding?

6 A. Yes, sir.

7 Q. And you've formed an opinion that that's
8 what -- that is the case here?

9 A. That is the case.

10 Q. Okay. So we have to move through each of
11 these one at a time just as if it was a separate
12 boundary line on a piece of property until we close the
13 loop, in your opinion anyway, and show that Becton
14 Dickinson is inside that property?

15 A. That is correct.

16 Q. All right. So let's talk in general before we
17 start with Claim 10. We're going to go right to that
18 process.

19 But before we start with Claim 10, can you
20 tell the jurors in general what Claim 10 protects?

21 A. Claim 10 and Claim 25, both part of the '077
22 patent, as I said earlier, concern themselves with sort
23 of a fluid containment system. It has the -- what I
24 call venting and tucking. And it also, in Claim 10, it
25 concerns the venting and tucking part.

1 In Claim 25 -- sorry to anticipate -- it
2 involves a two-step syringe with -- with also a similar
3 tucking feature.

4 Q. Okay. So let's go to -- first of all, what
5 did you do -- you have these words from the claim.

6 A. Uh-huh.

7 Q. What did you do to form an opinion that Becton
8 Dickinson is using this invention as claimed?

9 A. Well, what I do is I take these words, and, of
10 course, any words up there that have been construed by
11 the Court to have special meaning, I apply that special
12 meaning.

13 We just looked at retainer member as having a
14 special meaning.

15 And then I compare each one of those
16 limitations. They've been lettered just for
17 convenience. They don't appear that way in the patent.
18 And compare that to the actual product or drawings,
19 engineering drawings and manufacturing drawings supplied
20 by Becton Dickinson, represented to be the drawings that
21 were used to make their products.

22 Q. Okay. And have you prepared anything to help
23 us understand the comparison you made, the comparison
24 between BD structures and these words of this claim?

25 A. Yes, sir.

1 Within this slide, as we go down along each
2 one, there will be from time to time an animation or a
3 still picture or a page out of a document. There will
4 be some visual aids that will assist in what I'm about
5 to explain.

6 Q. Okay. So let's go to your presentation on
7 Claim 10.

8 And, first of all, the first thing up there
9 says the syringe plunger handle assembly and syringe
10 barrel combination for use in retractable syringe for
11 injecting fluids, comprising.

12 So what are we -- first of all, what's that
13 called?

14 A. Well, the opening line of a claim is called a
15 preamble. It sort of defines what this thing is about
16 generally. Is it a car? Is it a computer? Is it a new
17 fishing tackle system?

18 No. It's a syringe plunger handle assembly
19 and syringe barrel combination for use in a retractable
20 syringe for injecting fluids, comprising.

21 And comprising is a special word. It means
22 including at least the following things, and that's
23 where all the other things come.

24 Comprising in patent parlance is described as
25 an open-ended term. As long as you have all of the --

```
1 | these, let's say, eight other things, you can have three
2 | additional ones.  You can have -- as long as you have B
3 | through H, you can have some other things.
```

4 You can have bells and whistles and
5 everything, but you still infringe this claim, because
6 it says comprising. Comprising means you just have to
7 have these at minimum, but you can have other stuff and
8 it still infringes.

9 Q. Okay. So let's start with the first words,
10 other than the general description that's required for
11 this device to infringe.

12 The -- well, the term D --

13 A. Well, this is a picture of A, so now we can go
14 to B.

15	Q. Go to B.
----	-------------

16 A. The little green check means that it's
17 present.

18 MR. HARDIN: Oops, can we go back up to
19 B?

20 | There we go.

21 Q. (By Mr. Hardin) So the next thing that's
22 required is a hollow syringe body having an elongated
23 tubular wall, comprising an elongated barrel portion
24 having an open back end.

25 Does the Integra 3mL product have that?

1 A. Yes. And if we could show the figure that
2 goes with that.

3 This is the BD engineering drawing. Here is
4 an image of the actual product. And now we're going to
5 pull some parts away from it here so that you get down
6 to the -- actually, the simplest little part, which is
7 certainly a syringe body with an elongated tubular wall
8 and a -- with a elongated barrel portion. And it has an
9 open back end.

10 Q. Okay.

11 A. So this is met; this is satisfied; and we can
12 put a green check over on the right side for that one.

13 There you go.

14 Q. Okay. An elongated -- the next one is
15 elongated plunger disposed for reciprocation and sliding
16 sealed contact with the barrel portion of the body.
17 Does the 3ml have that?

18 A. Yes.

19 Here you can just see it's a pretty
20 straightforward demonstration, the fact that the plunger
21 is able to move back and forth within the barrel.

22 Q. Okay.

23 A. So that gets a green check mark right here.

24 Q. Okay.

25 A. Thank you.

1 Q. And next, the next requirement is the plunger
2 has a tubular wall and defining a head portion in front.

3 A. The plunger having a tubular wall defining a
4 head portion in the front, and we just saw that
5 animation happen quickly while we were speaking.

6 Here is the head portion of the plunger, and
7 here is the wall -- the wall of the plunger (indicates).

8 Q. Okay.

9 A. So this is also met by the Integra 3mL
10 product.

11 Q. All right. And the next requirement is?

12 A. So there's a check.

13 A back-end portion carrying a thumb cap.

14 And here is the plunger, and there's the thumb
15 cap, and it's just that straightforward.

16 So that gets a check as well.

17 Q. Okay. The next requirement is the hollow
18 interior comprising a retraction cavity.

19 A. Yes. And that's located between the head
20 portion and the thumb cap.

21 Well, you know this is the head portion; we
22 just covered that. You know this is the thumb cap, and
23 the retraction cavity -- and this is the part where the
24 needle's going to go -- is right there in between.

25 I should -- I should point out that in these

1 images, the front part of the barrel is not shown for
2 simplicity's sake. That's the detachable needle system.
3 So we're just showing this without it, just for
4 simplicity's sake.

5 Q. Now, the term retraction cavity, why -- why
6 does the term retraction cavity fit this space that
7 you're pointing to?

8 A. Because that's where the needle goes along
9 with the spring and just anything else that is going to
10 be retracted in the process of bringing the needle --
11 making the needle disappear.

12 Q. Okay. So we can put a check mark there, I
13 guess.

14 A. Yes, please.

15 Q. Another limitation: The thumb cap having an
16 outer side adapted to reside in close association with
17 the open back end of the plunger barrel when the plunger
18 is nearly fully depressed.

19 Does it have that?

20 A. Yes. Yes, it does. Here's the thumb cap.
21 And what we're going to do when we run the slide is
22 we're -- the animation, we're going to see what happens
23 and see that close association.

24 Q. Okay.

25 A. Now, that's highlighting the thumb cap and the

1 end of the -- the open end of the collar. And there's
2 some venting, which I'll talk about later.

3 And now you see here, it resides in close
4 association, essentially, inaccessible for grasping.

5 Q. Okay. Is that the last of our items on
6 this -- on this slide, I suppose?

7 A. Well, there's a BD document associated with
8 this -- this is the penultimate one.

9 Q. Oh, this is on the close association?

10 A. Right.

11 Q. You found a BD document in -- in -- in your
12 review that you thought bore on whether or not they were
13 using uncapping that had an outside edge and close
14 association?

15 A. Yes. In fact, this is from the BD document.
16 This one right here is -- as you zoom in on it, and you
17 can see just as I showed in the animation, that it is
18 down below. And it actually says the reason it does
19 that is to prevent manual removal of the plunger rod.

20 Q. So the Becton Dickinson engineers designing
21 this wanted the thumb cap inside the collar to prevent
22 manual removal?

23 A. Well, that's clear from this document.

24 Q. Okay. Okay. Let's move on to the next
25 requirement for this claim.

1 A. This is actually the final one: The plunger
2 having a vent.

3 And now watch what happens as the air gets
4 pushed out the sides and out the holes and out through
5 the end.

6 And so the -- now, this has the front end put
7 back on, because it's being operated -- actuated.

8 And -- and you can see the vents in operation.
9 So the 3mL Integra does, in fact, have vents. And I
10 think if you look at the next slide, we can take a look
11 at the drawing. This is a Becton Dickinson drawing that
12 was supplied to RTI during this litigation showing what
13 is -- functions as a vent hole in the plunger.

14 So the animation showed this -- showed the
15 arrow, the blue arrow flowing out through this. Well,
16 that's what it's flowing out through. So there's no
17 question, in my mind, that there's -- there's a vent
18 there.

19 Q. Now, we looked this morning a little bit
20 quickly at the Murray patent that had a vent in the
21 back, also.

22 A. Yes, sir.

23 Q. Is there -- is there a difference between the
24 way that Murray structure is drawn with respect to the
25 retracting piece and the way the BD operates with

1 respect to venting?

2 A. Well, the Murray one is different in the sense
3 that Murray has -- I mean, it's venting. But the Murray
4 one is there to vent the -- to prevent pressure build-up
5 behind a piston. It's subtle, but it's important.

6 The vent that Mr. Shaw invented and the vent
7 that's here would serve also, and more importantly, to
8 prevent air from pushing out the front. So -- so you
9 want to lower the pressure at the front end to prevent
10 splatter as described by Mr. Shaw in his patent.

11 Q. Now, so we have all the -- all the boundary
12 lines checked?

13 A. Oh, yes. That's the last one.

14 Q. Okay. And so this is your opinion using those
15 documents and that inspection of the -- of the 3mL
16 Integra.

17 Does that form the basis of your opinion
18 regarding the infringement question for that product on
19 Claim 10 of this patent?

20 A. Yes. It forms the basis.

21 And my conclusion is that the Integra 3mL does
22 infringe Claim 10 of the '077 patent.

23 Q. Okay.

24 A. Literally.

25 Q. Very good.

1 Now, we have another claim in this patent.

2 A. Yes, sir.

3 Q. Claim 25. How does this claim differ
4 generally from Claim 10?

5 A. In order to infringe this claim, you don't
6 have to have a vent, but you have to have two steps.
7 The plunger has to come to two separate steps unlike a
8 regular syringe.

9 Q. Okay. And, again, are we going to move
10 through the same general outline?

11 We're going to show the jurors -- because at
12 the end of the case, they're going to be -- they're
13 going to be asked by this Court whether or not this
14 product falls within the definition of the defined
15 claim.

16 We're going to move through each of these
17 limitations again?

18 A. Yes, sir.

19 Q. And have you got drawings and diagrams to show
20 this to help them?

21 A. I do. I do as well.

22 Q. Okay. Let's take a look at the preamble for
23 this claim.

24 A. The preamble, very brief, a tamper-proof
25 retractable syringe structure designed for one use,

1 comprising. And there's that word comprising.

2 So, once again, to infringe this claim, all
3 you have to do is have the one -- things that are
4 listed, regardless of what else you have, whatever bells
5 and whistles, it doesn't matter.

6 So the first limitation -- this is the
7 preamble and that, of course, is met. So there will be
8 a check there.

9 So now, here's the first true limitation: A
10 hollow syringe body comprising a syringe barrel having
11 an open back end.

12 Now, this is much like the previous claim.
13 I'm just showing it in a different way. Here's an
14 assembly drawing from Becton Dickinson showing the front
15 end of the barrel here and the back part of the barrel.
16 And here is that open back end. So this limitation is
17 met.

18 Q. Okay. And what's --

19 A. That's the drawing of the 3mL Integra.

20 Q. What's the Limitation C on your drawing?

21 A. It simply says that the barrel should have a
22 front-end portion containing a retraction mechanism
23 configured for operation by a plunger.

24 Now, this is the first time we see a very
25 detailed, color-coded, closeup of the 3ml syringe. So

1 when this -- when we deal with this, I'll try to be
2 thorough, just so to be clear.

3 Q. So right now, though, all that's required by
4 this claim is a retraction mechanism?

5 A. Correct. A retraction mechanism of any kind.

6 Q. Okay. So BD has a special kind, and we're
7 going to talk about it today, but for this -- for
8 purpose of this claim, if it's something -- a mechanism
9 that causes the needle to retract, it would fit the
10 claim?

11 A. Right. And it needs to be operated by the
12 plunger.

13 Q. Okay. All right.

14 A. And that's what you're about to see
15 happening -- well, we were.

16 Q. Okay.

17 A. Okay.

18 Q. Now, it says a plunger reciprocally mounted in
19 sliding sealed contact with the barrel.

20 A. Okay. This should be familiar. This is the
21 limitation very much like what was in Claim 10,
22 basically that it slides back and forth and functions
23 like a syringe.

24 So that one is quickly met.

25 Q. All right. And Limitation E is the plunger

1 having a thumb cap at its back and the -- for working
2 the plunger relative to the barrel and a front end
3 configured to operate the retraction mechanism.

4 A. Right. Very straightforward. Here's the
5 thumb cap. There's the front end (indicates).

6 This limitation is met.

7 Q. The front end has to operate the retraction
8 mechanism in some way?

9 A. That's correct, the front end.

10 Q. Okay.

11 A. Oh, there it was.

12 Q. All right. And the next limitation is?

13 A. Okay. E is met.

14 The next one is the plunger having -- and
15 here's the two-position part -- having a first tactile
16 position -- a tactile first position felt by the user
17 pressing the thumb cap at the end of travel of the
18 plunger in the barrel when the plunger is moved forward
19 to a stop.

20 And what happens is, as you deliver the
21 medication -- remember this black rubber part here is
22 not allowed to move. It's attached to the plunger.
23 That comes up against this blue part here and the red
24 part here. This is a bridge. This is the needle
25 holder, part of the barrel (indicates).

1 It comes to a stop. So that's the first stop
2 it comes to. You can feel it. Ah, I'm there.

3 So now that's met by the Integra 3mL.

4 Q. Okay. And the next requirement in this claim?

5 A. This one requires that the plunger has a
6 length such that when you are in that position, the back
7 end is still sticking out so you can grab it.

8 Unlike before when in the end you wanted to be
9 tough so you can't get at it, you want to make sure that
10 when you're in that first position, you can still get at
11 it so the nurse can grab the end and suck the medication
12 up from the vial into the syringe.

13 Q. So -- so the first position, again, is she can
14 take it all the way down to the stop, and it's still
15 sticking out above the collar?

16 A. Correct, because the barrel -- the plunger is
17 long enough.

18 Q. Okay. And then she can grab it and pull it
19 back out and suck medicine up?

20 A. Correct.

21 Q. And then where is the second position?

22 A. The second position happens during the
23 retraction event.

24 After you deliver the medication, you go past
25 the first stop to the second stop and deliver the

1 medication. And the medication is already delivered --
2 I'm sorry -- at the first stop. And the second stop
3 goes forward and -- and creates -- the retraction occurs
4 and then the safety aspect in the back occurs.

5 Q. Okay. Let's see the next requirement of the
6 claim.

7 A. And we just sort of prespoke about this. You
8 can see the 3ml being activated. You see the retraction
9 mechanism flying back into here. And now you've got
10 this limitation. Here it's slightly different wording.
11 Simultaneously lodging the thumb cap in the open back
12 end, thereby rendering the thumb cap inaccessible --
13 inaccessible -- I'm sorry -- for grasping.

14 You can see that you can't grab that with
15 your -- with your thumb and forefinger, your fingers.

16 Q. Okay. Could you dig it out of there with a
17 fingernail?

18 A. If you had a good long fingernail, perhaps if
19 you played guitar, or a pen knife.

20 Q. Okay.

21 A. Sure, you could pry it out.

22 The whole -- the whole purpose is that you
23 can't do this (indicates) and have it -- have it come
24 out. It's perfectly safe without having to use extra
25 force to engage some kind of lock.

1 Q. Okay. Is it your opinion, therefore, that
2 this 3mL Integra infringes, meets all the limitations,
3 and infringes Claim 25 of the '077 patent?

4 A. Yes. It is my opinion that the 3mL Integra
5 literally infringes every limitation of Claim 25 of the
6 '077 patent and, therefore, infringes.

7 Q. Okay. Thank you.

8 Let's move forward.

9 THE COURT: This is probably a convenient
10 breaking point for our lunch break.

11 MR. HARDIN: Thank you, Your Honor.

12 THE COURT: We'll have our lunch recess.

13 Try to be back in time to properly start at 1:30.

14 We will be in recess.

15 COURT SECURITY OFFICER: All rise.

16 (Recess.)

17 * * * * *

18

19

20

21

22

23

24

25

CERTIFICATION

I HEREBY CERTIFY that the foregoing is a true and correct transcript from the stenographic notes of the proceedings in the above-entitled matter to the best of my ability.

/s/_____
SUSAN SIMMONS, CSR
Official Court Reporter
State of Texas No.: 267
Expiration Date: 12/31/10

Date

/s/_____
JUDITH WERLINGER, CSR
Deputy Official Court Reporter
State of Texas No.: 731
Expiration Date: 12/31/10

Date